Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
1 
  
An International Multicenter, Adaptive, Randomized Double -Blind , Placebo -
Controlled  Trial of the Safety , Tolerability  and Efficacy of Anti-Coron avirus 
Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult  
Hospitalized Patients  at Onset of Clinical Progression of COVID -19 
 
Short Title: Inpatient Treatment with Anti-Coronavirus Immunoglobulin ( ITAC ) 
 
INSIGHT Protocol Number: 013 
 
Version:  1.0, 20 August 2020  
 
Funded by the National Institute of Allergy and Infectious Diseases (NIAID),  
National Institutes of Health (NIH) and  carried out by the International Network for Strategic 
Initiatives in Global HIV Trials (INSIGHT)  
Study Sponsor:  University of Minnesota  
 
In collaboration with four International Coordinating Centers (ICCs) of the INSIGHT 
Network:  
-Copenhagen HIV Programm e (CHIP) - Copenhagen, Denmark  
-Medical Research Council (MRC) Clinical Trials Unit at University College London 
(UCL) -London, United Kingdom  
-The Kirby Institute, University of New South Wales - Sydney, Australia  
-The Institute for Clinical Research at the Veterans Affairs Medical Center - Washington, 
D.C., USA   
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
2 
 TABLE OF CONTENTS  
TABLE OF CONTENTS  ................................ ................................ ................................ .........  2 
LIST OF TABLES  ................................ ................................ ................................ ...................  5 
LIST OF FIGURES  ................................ ................................ ................................ ................  5 
1 PROTOCOL SUMMARY  ................................ ................................ ................................  6 
 Synopsis  ................................ ................................ ................................ ...................  6 1.1
1.1.1  Rationale for Proposed Clinical Study  ................................ ................................  6 
1.1.2  Study Design  ................................ ................................ ................................ ...... 6 
2 INTRODUCTION  ................................ ................................ ................................ ............  8 
 Study Rationale  ................................ ................................ ................................ ........  8 2.1
 Background  ................................ ................................ ................................ ...............  9 2.2
2.2.1  SARS -CoV-2 Infection and Coronavirus Disease 19 (COVID -19) ......................  9 
2.2.2  Natural History of COVID -19 ................................ ................................ ..............  9 
2.2.3  Risk Factors for Clinical Progression  ................................ ................................  11 
2.2.4  Hospitalization of People with COVID -19 ................................ .........................  12 
2.2.5  Viral Kinetics of SARS -CoV-2 Infection  ................................ ............................  12 
2.2.6  Immune Responses to SARS -CoV-2 Infection  ................................ .................  13 
2.2.7  Current Treatment Strategies for COVID -19 ................................ ....................  14 
2.2.8  Hyperimmune Intravenous Immunoglobulin (hIVIG) ................................ .........  16 
2.2.9  Study Treatments  ................................ ................................ .............................  17 
3 RISK/BENEFIT ASSESSMENT  ................................ ................................ ....................  20 
 Know n Potential Risks  ................................ ................................ ............................  20 3.1
3.1.1  Blood Draw and IV Catheterization  ................................ ................................ .. 20 
3.1.2  Study Treatments  ................................ ................................ .............................  20 
3.1.3  Confidentiality and Privacy  ................................ ................................ ...............  23 
 Known Potential Benefits  ................................ ................................ ........................  23 3.2
4 OBJECTIVES AND ENDPOINTS  ................................ ................................ .................  23 
 Primary  Objectives and Primary Endpoint  ................................ ..............................  23 4.1
4.1.1  Rationale for Primary Endpoint at Day 7  ................................ ..........................  24 
 Secondary Objectives  ................................ ................................ .............................  25 4.2
5 STUDY DESIGN  ................................ ................................ ................................ ...........  28 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
3 
  Overall Study Design  ................................ ................................ ..............................  28 5.1
 Rand omization  ................................ ................................ ................................ ........  28 5.2
 Blinding  ................................ ................................ ................................ ...................  28 5.3
 Distribution of Anti -Coronavirus hIVIG to Clinical Sites  ................................ ...........  29 5.4
 Sample Size Assumptions  ................................ ................................ ......................  30 5.5
5.5.1  Primary Analysis ................................ ................................ ...............................  30 
5.5.2  Key subgroup analysis  ................................ ................................ .....................  31 
5.5.3  Key secondary outcomes  ................................ ................................ .................  32 
 Schedule of Assessments  ................................ ................................ .......................  33 5.6
 Approach to Intercurrent Therapies and Clinical Trial Co -enrollment  .....................  33 5.7
6 SCIENTIFIC RATIONALE FOR THE STUDY  ................................ ...............................  34 
7 STUDY POPULATION ................................ ................................ ................................ .. 34 
 Inclusion Criteria  ................................ ................................ ................................ ..... 34 7.1
 Exclus ion Criteria  ................................ ................................ ................................ .... 35 7.2
 Costs to Participants  ................................ ................................ ...............................  36 7.3
8 STUDY PRODUCT  ................................ ................................ ................................ ....... 36 
 hIVIG and Placebo  ................................ ................................ ................................ .. 36 8.1
8.1.1  hIVIG Description  ................................ ................................ .............................  36 
8.1.2  hIVIG Dose  ................................ ................................ ................................ ....... 36 
8.1.3  hIVIG Administration  ................................ ................................ ........................  37 
8.1.4  Preparation/Handling/Storage/Accountability  ................................ ...................  38 
 Remdesivir Background Therapy  ................................ ................................ ............  38 8.2
8.2.1  Rationale  ................................ ................................ ................................ ..........  38 
8.2.2  Description  ................................ ................................ ................................ ....... 38 
8.2.3  Administra tion ................................ ................................ ................................ .. 38 
8.2.4  Contraindications ................................ ................................ ..............................  39 
8.2.5  Dose Modification  ................................ ................................ .............................  39 
8.2.6  Prep aration/Handling/Storage/Accountability  ................................ ...................  39 
 Standard of Care Therapy  ................................ ................................ ......................  39 8.3
8.3.1  Thromboprophylaxis and diagnosis of thrombotic complications  .....................  39 
8.3.2  Other Standard Supportive Care  ................................ ................................ ...... 40 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
4 
 8.3.3  Cautions and Contraindications  ................................ ................................ ....... 40 
8.3.4  Infection Control Measures  ................................ ................................ ..............  41 
9 STUDY ASSESSMENTS AND PROCEDURES  ................................ ...........................  41 
 Screening/Baseline, Follow -up and Endpoint Assessments  ................................ ... 41 9.1
9.1.1  Screening/Baseline Assessments  ................................ ................................ .... 41 
9.1.2  Follow -up assessments  ................................ ................................ ....................  43 
9.1.3  Stored Samples and Future Research  ................................ .............................  44 
10 SAFETY REPORTING  ................................ ................................ ...............................  44 
 Definitions  ................................ ................................ ................................ ............  45 10.1
10.1.1  Adverse E vent (AE)  ................................ ................................ ......................  45 
10.1.2  Criteria for Seriousness ................................ ................................ .................  46 
10.1.3  Unanticipated Problems  ................................ ................................ ................  46 
10.1.4 Severity  ................................ ................................ ................................ .........  46 
10.1.5  Causality  ................................ ................................ ................................ ....... 47 
10.1.6  Expectedness  ................................ ................................ ...............................  47 
 Schedule for Data Collection and Reporting of Specific Events  ..........................  48 10.2
10.2.1  Infusion -related reactions  ................................ ................................ ..............  48 
10.2.2  Targeted Laboratory abnormalities  ................................ ...............................  48 
10.2.3  Clinical adverse events of any grade severity on Da ys 0, 1, 3, 7 and 28  ...... 48 
10.2.4  Incident Grade 3 and 4 clinical adverse events through Day 7  .....................  48 
10.2.5  Protocol -specified exempt events  ................................ ................................ . 49 
10.2.6  Reportable SAEs  ................................ ................................ ..........................  49 
10.2.7  Unanticipated Problems (UPs)  ................................ ................................ ...... 50 
10.2.8  Deaths ................................ ................................ ................................ ...........  50 
 Medical Monitor  ................................ ................................ ................................ ... 50 10.3
 Treatment Interruption or Discontinuation  ................................ ...........................  50 10.4
 Halting Rules  ................................ ................................ ................................ ....... 51 10.5
11 EVALUATION  ................................ ................................ ................................ ............  51 
 Data Analysis  ................................ ................................ ................................ ....... 51 11.1
 Ethical Conduct of the Study  ................................ ................................ ...............  54 11.2
 Data Monitoring by an Independent DSMB  ................................ .........................  54 11.3
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
5 
 12 PROTECTION OF HUMAN SUBJECTS AND ETHICAL CONSIDERATIONS  ..........  55 
 Participating Clinical Sites and Local Review of Protocol and Informed Consent  55 12.1
 Informed Consent of Study Participants  ................................ ..............................  55 12.2
 Confidentiality of Study Participants  ................................ ................................ .... 56 12.3
 Regulatory Oversight  ................................ ................................ ...........................  56 12.4
APPENDIX  A SAMPLE INFORMED CONSENT FORM  ................................ ..................  57 
APPENDIX B  SCHEDULE OF ASSESSMENTS  ................................ .............................  85 
APPENDIX C  INSIGHT 013 PROTOCOL TEAM  ................................ .............................  87 
APPENDIX D  REFERENCES ON THE INSIGHT WEBSITE  ................................ ...........  88 
APPENDIX E  LIST OF ACRONYMS  ................................ ................................ ...............  89 
APPENDIX F  CLINICAL CATEGORICAL DEFINITIONS FOR ORDINAL OUTCOME  .... 92 
APPENDIX G  NATIONAL EARLY WARNING SCORE (NEWS)  ................................ ...... 93 
13 REFERENCES ................................ ................................ ................................ ...........  95 
 
LIST OF TABLES  
Table 1. Hypothesized percentage of participants in each category on Day 7 in the hIVIG 
and placebo groups based on aforementioned assumptions  ................................ ...............  31 
Table 2.  Adverse Event Data Collection Overview  ................................ ..............................  45 
Table 3. Generic AE Grading Scale  ................................ ................................ .....................  47 
 
LIST OF FIGURES  
Figure 1. Natural History of COVID -19 ................................ ................................ .................  11 
Figure 2. Example of Allocation of hIVIG to 24 Site Pharmacies  ................................ .........  30 
  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
6 
  PROTOCOL  SUMMARY  1
 Synopsis  1.1
1.1.1  Rationale for Proposed Clinical Study  
In December 2019, the Wuhan Municipal  Health  Committee identified an outbreak of 
viral pneumonia cases of unknown cause. Coronavirus ribonucleic acid ( RNA ) was 
quickly identified in some of these patients. This novel coronavirus has been 
designated severe acute respiratory syndrome coronavirus 2 (SARS -CoV-2), and the 
disease caused by this virus has been designated coronavirus disease 2019  (COVID -
19). There were 59 confirmed cases on January 5, 2020 , 2118 cases on January 26, 
2020, rising to more than 20 million confirmed cases and 750,000 deaths as of 
August 16, 2020 according to various international health reporting agencies.  
Hyperimmune intravenous immun oglobulin (hIVIG) to SARS -CoV-2, derived from the 
plasma of individuals who recover and develop neutralizing antibodies, is a  potentially 
useful therapeutic approach to COVID -19. Augmentation of the humoral immune 
(antibody ) response using passive immunotherapy with hIVIG to SARS -CoV-2 at the 
onset of clinical progression  before end -organ failure has developed may reduce the 
subsequent risk of further disease progression and death.   
1.1.2  Study Design  
This protocol will serve as a p latform for assessing treatments for adult  patients  
hospitalized for medical management of  COVID -19 without related  serious end-organ 
failure . Trials will involve sites around the world strategically chosen to ensure rapid 
enrol lment.  Initially, th is trial will compare hIVIG with matched placebo , when added 
to standard of care (SOC),  for preventing further disease progression and mortality 
related to COVID -19. SOC will include remdesivir unless it is contraindicated  for an 
individual patient .  
In future versions of the protocol , one or more drugs from a different class and with 
different mechanism s of action may be studied.  Such treatment s could be studied 
along with hIVIG if it is found effective and safe in this initial version of the protocol.   
The primary endpoint of this trial in hospitalized patients is an ordinal outcome based 
on the patient’s clinical status on  Day 7. It includes  7 mutually exclusive categories  
capturing the range of organ dysfunction  that may be associated with progress ion of 
COVID -19, such as  respiratory dysfunc tion and  coagulation -related complications  
(see Appendix  F for full definition) : 
7. Death  
 
6. End-organ failure  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
7 
  
5. Life-threa tening end-organ dysfunction  
 
4. Serious end-organ dysfunction  
 
3. Moderate end -organ dysfunction   
 
2. Limiting symptoms due to  COVID -19 
 
1. No limiting  symptoms  due to COVID -19 
Secondary endpoints include time to the 3 least favorable categories, time to the 2 
most favorable categories, and the pulmonary only and thrombotic only components 
of the primary ordinal outcome.  Mortality, adverse events  (AEs) , including infusion 
reactions , and  biological correlat es of therapeutic activity  are also assessed . Because 
there is no established endpoint for evaluating the clinical efficacy of treatments for 
COVID -19, other clinically relevant outcomes, including outcomes used in other 
COVID -19 treatment trials, will be recorded . Thus, the randomized groups (initially 
hIVIG + SOC versus  placebo + SOC ) can be compared for multiple outcomes , and 
results can be  compared or combined with other trials.   
Participants  will be randomized  (1:1) to a single infusion of hIVIG  + SOC  or placebo  + 
SOC  on the day of randomization (Day 0) . Participants  taking remdesivir prior to 
randomization may be enrolled  if eligibility criteria are met . Randomized pa rticipants  
who were not taking  remdesivir before randomization will start taking r emdesivir 
immediately following the infusion of hIVIG or placebo  unless remdesivir is 
contraindicated . Participants  will be followed for 28 days  and, if the trial goes to 
completion, the primary analysis will be completed after all participants are followe d 
for 28 days .  
The planned sample size is 500 participants  (250 per group) . After 150 participants 
are enrolled, sample  size will be re -estimated , by investigators who are blinded to 
interim treatment results using pooled outcome data.  
The study populati on will include  consenting hospitalized patient s with C OVID -19 
who have had COVID -19 symptoms ≤ 12 days , and who do not have life-threatening 
organ dysfunction or organ failure .  
Many other  clinical trials evaluating treatments for COVID -19 are either ongoing or 
being planned.  If findings from another trial have implications for  the design and 
conduct of this trial, the protocol may be modified depending on the strength of the 
trial results and the target population studied.   
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
8 
 An independent Data and Safety Monitoring Board (DSMB) will review  interim data 
and use pre -specified guidelines for early termination of the trial or protocol 
modification . The DSMB will also be consulted concerning pro tocol modifications for 
reasons described above (e.g., sample size re -estimation  or other aspects of the 
design resulting from emerging data).  All protocol modifications will be discussed with 
the independent DSMB.  Protocol amendments will be submitted to ethic s committees  
(ECs)  and a central institutional review board ( IRB) in the United States  of America 
(US). 
After consent and eligibility has been determined, a single infusion of hIVIG or 
placebo will be administered on the day of randomization (Day 0).  Remdesivir 
infusions will follow th e hIVIG/placebo infusion. Any i nfusion reactions and 
interruption s of the planned hIVIG/placebo infusion  will be recorded.  The ordinal 
outcome  will be assessed throughout follow -up, including on Day 7 for the primary 
endp oint. On Day 0 (pre -hIVIG/placebo infusion ), and on Days  1, 2, 3, 7, and 28, a 
blood sample will be obtained to centrally measure neutralizing antibody levels along 
with total immunoglobulin G (IgG) concentrations  and its subclasses, immunoglobulin 
A (IgA), and immunoglobulin M (IgM); for participants at selected sites an additional 
blood sample for these  measurements will be obtained at Day 90 . Serious Adverse 
Events (SAEs), including deaths from any cause, will be  collected through Day 28.  
hIVIG infusion related events of any grade will be  collected.  Grade 3 and 4 AEs will 
be collected through Day 7.   AEs of any grade experienced on Days 1, 3, 7, and 28 
will be  recorded.  
 INTRODUCTION  2
 Study Rationale  2.1
COVID -19 is a  respiratory disease caused by a novel coronavirus (SARS -CoV-2). 
While some cases are mild or asymptomatic, progressive disease can result in 
hospitalization, requirement for mechanical ventilation, and is a cause  of substantial 
morbidity and mortality .1 While the most common mode of disease progression is 
progressive respiratory failure following the development of pneumonia, other severe 
complications including thrombosis and ischemia are increasingly recognized .2,3  
There is currently no vaccine to prevent infection with SARS -CoV-2 and no  licensed 
therapeutic agent to treat COVID -19; emergency use authorizations and expanded 
access schemes have been instituted  for certain interventions (including 
convalescent plasma a nd remdesivir, described below) prior to licensure . Several 
clinical trial s utilizing novel drugs and repurposing older agents have been 
implemented  to investigate the treatment of adults hospitalized with  severe  COVID -
19 (see Section 2.2.7 ).  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
9 
 Our understanding of the humoral immune response is evolving, with some evidence 
that responses are variable between individual s and delayed in some cases . It may  
therefore  be that viral replication may lead to extensive tissue damage and 
inflammatory response s in the lungs and other organs before the development of 
neutralizing antibodies . Augmentation of the humoral immune  response to SARS -
CoV-2 using passive immunotherapy  with hIVIG to SARS -CoV-2 in hospitalized 
patients at the onset of clinical progression  but before end -organ failure has 
developed may thus reduce the subsequent risk of further disease progression and 
death.   
 Background  2.2
2.2.1  SARS -CoV-2 Infection and Coronavirus Disease 19 (COVID -19) 
In December 2019, the Wuhan Municipal Health Committee identified an outbreak of 
viral pneumonia cases of unknown cause. A novel coronavirus was rapidly identified 
by sequencing and named severe acute respiratory syndrome coronavirus 2 (SARS -
CoV-2), and the illness caused by infection with SARS -CoV-2 has been named 
coronavirus  disease 2019 (COVID -19).4 While SARS -CoV-2 mostly causes a mild 
respiratory illness, some individuals , particularly  those who are elderly  5,6 and have 
comorbidities7 may progress to severe disease requiring hospitalization, mechanical 
ventilation in intensive care units , and death. As of 28 June 2020, just 14 weeks 
following  the declaration of a pandemic on 11 March 2020 by the World Health 
Organiza tion (WHO) ,4 there ha ve been  more than 20 million cases diagnosed and 
more than 750,000 deaths across  185 countries.1 Over  100,000 cases continue to be 
reported daily.4 
2.2.2  Natural History of C OVID -19 
SARS -CoV-2 has a median incubation period of 4 days (interquartile range 2 -7 
days)8 and the mean serial interval defined as the time between a primary case -
patient (infector) having symptom onset and a secondary case -patient (infectee) 
having symptom onset for COVID -19 was calculated as 3.96 (95% confidence 
interval [ CI] 3.53–4.39) days.9 COVID -19 illness is predominantly a respiratory 
disease typified by upper respiratory symptoms in mild cases and pneumonia, 
respiratory failure and acute respiratory distress syndrome (ARDS) in advanced 
disease. Initial symptoms typically involve the upper respiratory tract with cough, sore 
throat and malaise.  Fever is present in approximately 44 -98% of cases. Notably , 
persons with COVID -19 often complain of loss of smell or taste.  
Advanced complications of COVID -19 illness include cytopenias (lymphopenia, 
thrombocytopenia and anemia), and a cute cardiac events (raised troponin, changes 
on electrocardiogram), acute renal injury and renal failure, liver impairment, and 
neurological events including acute cerebrovascular events, impaired consciousness 
and muscle injury and thrombotic events.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
10 
 The natural history of COVID -19 as we understand it thus far is illustrated in Figure 1. 
In most patients (approximately 80%) symptoms resolve without the need for 
intervention within five to seven days of symptom onset up to a maximum of 14 days. 
However, approximately 20%  of patients  show signs of clinical disease progression, 
most notably  pneumonia , around day 3 to 8 following symptom onset.  Other 
manifestations of disease progression include thrombotic episodes including stroke 
and myocardial infarction  (MI). This resembles the documented 6 -8 fold excess risk  
of thrombosis  when patients a re infected with influenza.10  
A proportion of those who progress then further deteriorate, including with the 
development of  ARDS around 1 -5 days after pneumonic symptom onset.5,11,12,13  
Acute kidney injury necessitating dialysis and failure of other organs may also occur  
at this severe stage of  disease.  
 
Of the nearly 1099 persons described in the Wuhan cohort, 16.0% had severe 
disease at presentation. 67 persons (6.1%) reached a composite primary endpoint of 
intensive care admission, mechanical ventilation and death; two -thirds had presented 
with severe disease.8,14 As described below, outcomes for those requiring 
mechanical ventilation and with other manifestations of end -organ failure are poor, 
and ap proaches to prevent this late stage of the disease am ong those with early 
evidence of progression are critically needed.  
 
In this trial, we aim to enroll patients hospitalized for medical management of COVID -
19 at the onset of clinical progression but before end -organ failure has developed : the 
time period of their infection which is shaded light orange in Figure 1. The majority of 
these patients will have e merging evidence of pneumonia, bu t recognizing the 
expanding range of organs involved in clinical progression of COVID -19, neither the 
inclusion criteria nor primary endpoint are limited only to assessment of pneumonia 
and related clinical progression .  
 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
11 
 FIGURE 1. NATURAL HISTORY OF COVID -19  
 
 
2.2.3  Risk Factors for Clinical Progression  
Studies investigating risk factors for progression  of COVID -19 and related hospital 
admission are currently few in the literature. Reports to date have predominately 
been conducted in individuals already hospitalized. These includ e a mix of descriptive 
information on the patients as well as estimates of associations between patient  
characteristics and disease severity.  Older age has been found to be stron gly related 
to greater severity14,15 and poorer outcome as ha s the presence of conditions such as 
hypertension, diabetes and coronary heart disease .12,14,16  Other risk factors identified 
include cigarette smoking14,15,17 and raised body mass index ( BMI).18,19,20,21  Gender 
has not shown a consistent relationship with disease severity.14,22  Specific symptoms 
at presentation that have notably been associated with greater likelihood of 
progression to more severe disease include shortness of breath and elevated  body  
temperature .14,23  
The COVID -19–Associated Hospitalization Surveillance Network (COVID -NET) report 
on 1482 persons who were hospitalized in 14 states in the United States  of America 
(US) in March 2020 show ne arly 75% were aged over 50 years, and nearly 90% had 
at least one or more underlying comorbid illness .24  
Based on 2.6 million users of the COVID Symptom Tracker App, predominantly in the 
United Kingdom, being older, obese, diabetic , or suffering from pre -existing lung, 
heart or renal disease placed participants at increased risk of visiting hospital with 
COVID -19.25 Pre-existing lung disease and diabetes were consistently associated 
with a higher risk of requiring respiratory support.25 A meta -analysis showed that 
cardiac injury as measured by a high sensitive troponin was associated with higher 
mortality, higher need for intensiv e care unit (ICU)  care, and severe COVID -19 
disease.26 

Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
12 
 2.2.4  Hospitali zation of People with COVID -19 
Countries and jurisdictions differ in the clinical management of COVID -19 patients. 
Early in the epidemic, faced with small numbers of infected persons, some resource -
rich countries such as Singapore elected to admit all persons with COVID -19 illness 
regardless of symptom severity to facilitate strict isolation.  Admission for reasons of 
public health or quarantine, rather than medical management, continues to b e a 
requirement in some countries notably in Asia. Elsewhere, it is more common for 
those with mild illness to be  advised to self -isolate at home, while only those severely 
unwell are admitted for medical management.  
Thresholds for ICU management also dif fer globally and  are likely to vary significantly 
even within individual countries at different stages of the epidemic. For example, at 
the epidemic peak procedures commonly performed only in ICU may be extended to 
other care areas, while patients who migh t otherwise have been considered for ICU 
admission may be palliated if clinical services are overwhelmed.  
Repor ted mortality rates for those who develop end-organ failure  requiring intensive 
support , including those admitted to ICU , differ widely.  Amongst 1591 ICU patients 
from the Lombardy region in Italy, hardest hit by COVID -19, 88% required 
mechanical ventilation and 11% noninvasive ventilation.27 The ICU mortality rate was 
26%. Of 1043 patients with available data, 709 (68%) had at least 1 comorbidity and 
509 (49%) had hypertension, 21% had cardiovascular disease . Younger patients 
(≤63 years) compared to older patients, had lower ICU mortality and  higher rates of 
discharge from ICU. The median length of stay in the ICU was  9 days though 58% 
remained in ICU at time of report.27 In one report of  the Chinese experience in 
Wuhan, 31 of 32 persons who required mechanical ventilation died.5 In the United 
Kingdom, of the 4078 COVID -19 patients a dmitted into critical care with reported 
outcomes, 50.7% died in ICU ; those requiring advanced respiratory support and renal 
support had worse outcomes .28 These data underline the importance of attenuating 
the disease in its early phase prior to the development of end -organ failure and the 
requirement of intensive care.  
2.2.5  Viral Kinetics  of SARS -CoV-2 Infection  
Viral kinetic studies have demonstrated extensive  SARS -CoV-2 viral replication in the 
pharynx just before and early after symptom onset.29 Viral R NA shedding from 
pharynx gradually wanes as sympt om resolve  though v iral RNA is still detectable 
weeks after symptom resolution .29,30,31 Median duration of viral shedding was 20 days 
in survivors (longest 37 days), but SARS -CoV-2 was detectable until death in non -
survivors.6 Whether this is viable virus with the potential for continued transmission 
remains uncertain. RNAemia has been reported but  is relatively rare .30,32  Viral 
detection in sputum is higher and outlasts pharyngeal swabs in those with 
pneumonia.33  Persons with asymptomatic disease clear their virus faster than 
symptomatic individuals.34 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
13 
 The co ntribution of ongoing viral replication to disease progression in the third most 
severe stage of COVID -19 (i.e. on ventilator or extra -corporeal membrane 
oxygenation  [ECMO ]) is unclear, but likely minor  as we hypothesize that any organ 
damage from the infection has likely occurred already  and the predominant drivers of 
progression to severe disease/ ARDS  are those of the uncontrolled local and systemic 
immune response . 
2.2.6  Immune Responses to SARS -CoV-2 Infection  
Notwithstanding the observed high viral loads , and progression of viral shedding from 
the upper to lower respiratory tract  in those with progressive disease , the humoral 
immune response to SARS -CoV-2 appears variable  and may be slow. While data are 
still emerging, it appears that in a significant pro portion of  cases , antibody responses 
are not yet evident at the time (day 5 -7) when  disease progression and 
hospitalization  most commonly occur, supporting a role for supplementation of the 
antibody response at that time point .  
Two large series have descr ibed antibody responses (IgG and IgM) . In the first,  
samples from 82 confirmed and 58 probable cases of COVID -19 in a cross -sectional 
analysis demonstrated IgG detection 14 ( interquartile range [IQR] 10-18) days after 
symptom onset, with IgM detected median  of 5 days  (IQR 3 -6) after symptom onset. 
Antibodies were absent in around 22% of individuals at assessment (IgM), and IgM 
was most commonly absent in those assessed early (within 7 days of symptom 
onset)].35 In the second  study of 262 patients who provided 363 samples , antibody 
levels were examined by days from symptom onset.  IgM antibodies were detectable 
in just under 40% of patients at day 5 -7, rising to 50% at day 8 -10, while interestingly 
IgG wa s detectable in a slightly higher proportion at those time points : just over 50% 
at day 5 -7, rising to 60% at day 8 -10.36 This series was drawn from hospitalized 
patients, but the severity of illness and any relationship with disease outcomes w ere 
not descr ibed. Both studies show considerable individual variation in antibody 
kinetics. Further l ongitudinal studies are underway and will better characterize the 
kinetics of these responses in individuals.  
SARS -CoV-2 infection may also induce significant changes in elements of the cellu lar 
immune response. As the disease process  progresses, the peripheral lymphocyte 
count typically declines. The depletion of peripheral lymphocytes likely reflect s 
translocation to the pulmonary tissue. The extent that this influx exclusively is helpful 
to the host, or possibl y may contribute adversely to disease severity is currently 
unclear. In severe cases th is decline in CD4+ and CD8+ lymphocytes is also 
associa ted with an increase in  activated CD4 + and CD8 +, increases in key 
proinflammatory cytokines including interleukin 6 ( IL-6), and increases in natural killer 
(NK) cells.37,38 Trials assessing the use of various immunomodulatory agents with the 
aim of dampening  this migration and systemic inflammation are underway, and may 
help to clarify this.   
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
14 
 2.2.7  Current Treatment Strategies for COVID -19 
There has been no proven therapy for COVID -19, and no international standard of 
care has been established, though many  clinical trials are underway. Approaches 
include direct anti -virals, including repurposed drugs found in vitro to have activity 
against SARS -CoV-2; immune modulators especially in  patients with  advanced 
disease, and modifiers of other pathophysiological p athways implicated in disease 
progression, including potentially anticoagulants and anti -platelet agents.  In certain 
regions, local standards of care have been established, generally with agents 
hypothesized to have clinical activity but where robust compa rative data are not yet 
available. For example, lopinavir, hydroxychloroquine, and favip iravir have all seen 
widespread use in hospitalized patients in different regions.  
The most promising current antiviral agent is remdesivir, a nucleotide analogue 
previously studied for  Ebola .39  A preliminary re port of the  National Institute of Allergy 
and Infectious Diseases (NIAID)  Adaptive COVID -19 Treatment Trial (ACTT)  showed 
that participants receiving remdesivir  had a shorter median time to recovery  
compared with those receiving placebo  (11 vs 15 days ; p<0.001). There was a trend 
toward a  survival benefit  after 14 days; estimates of  mortality were  7.1% and 11.9% 
(hazard ratio  [HR]=0.70; 95% CI: 0.47 -1.04).40 In contrast, a smal ler randomized 
study from China did not show a significant benefit for remdesivir in a similar 
hospitalized population (HR for time to clinical improvement 1 .23 [95% CI 0 .87–
1.75]); however th at trial was stopped early due to slow enrol lment and power was 
substantially less than planned (58% instead of 80%) .41 A number of other remdesivir 
trials are ongoing  and may clarify the extent of its therapeutic effect and other issues 
including optimal dosing and optimal timing of therapy . 
Based on the findings of  ACTT, remdesivir will be provided to all study participants  as 
SOC  unless contraindicated for an individ ual patient . As in ACTT, remdesivir will be 
administered as a 200 milligram ( mg) IV loading dose following the hIVIG/placebo 
infusion, followed by a 100 mg once -daily IV maintenance dose while hospitalized up 
to a 10 day total course.  Participants  taking r emdesivir prior to randomization will 
continue their daily remdesivir infusions while hospitalized up to a 10 day course.  
Other chemotherapeutic agents with hypothesized direct antiviral activity undergoing 
clinical study include antimalarial agents , hydroxychloroquine  and chloroquine, 
lopinavir -ritonavir (protease inhibitors)  and favipiravir  (an RNA -dependent RNA 
polymerase inhibitor ). Despite some early trials that did not establish the efficacy of  
high-dose chloroquine42 and lopinavir -ritonavir ,43 and uncontrolled  studies showing 
minimal benefit and possible harm  with hydroxychloroqu ine and azithromycin,44 these 
agents along with favipiravir  have been incorporated into some local institutional 
protocols as SOC , especially in patients hospitalized with advanced and progressive 
disease.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
15 
 Other agents under exploration modulate pathophysiological pathways implicated in 
disease progression. Given the apparent role of excessive IL -6 production in patients 
with advanced disease, tocilizumab and other inh ibitors of IL -6 and associated 
cytokine pathways (such as Janus kinase, JAK, inhibitors) are all under evaluation, 
and off -label use of tocilizumab in critical illness is common in some settings. 
Similarly given the apparent role of platelet dysfunction an d pro -coagulant effects of 
SARS -CoV-2 infection, there is interest in the use of antiplatelet agents and 
anticoagulants especially at the onset of progressive disease.  
A further promising line of approach  is the use of passive immunotherapies to 
enhance t he host immune response to SARS -CoV-2 infection, potentially enhancing 
viral control and limiting disease progression.  Convalescent plasma, generic 
intravenous immunoglobulin (IVIG) and hIVIG to COVID -19 are all gaining interest. 
While their characteristic s differ, convalescent plasma and hIVIG  are examples of 
passive antibody therapy involving administration of antibodies against SARS -CoV-2 
as prevention or therapy . High doses of standard IVIG have also been hypothesized 
to be useful for their immunomodula tory effects (as for example in their use in 
immune thrombocytopenia ) and  are under evaluation as described below . The 
concept of passive immunother apy is based on the historical concept of serotherapy 
developed in the 1890s where serum from immunized anim als containing an antitoxin 
factor that could neutralize the toxin and  be transferred onward to non -immune 
animals offered protection.45,46  
The most widely used of these agents at present is c onvalescent plasma containing 
COVID -19 antibodies (CCP) . CCP is  collected by apheresis from individuals who 
have recovered from COVID -19 and tested for the presence of SARS -CoV-2 
antibodies, preferably with a target neutralizing antibody titer. Despite relatively 
widespread use, data for its efficacy in SARS -CoV-2/COV ID-19 is very limited . 
Convalescent sera were previously  evaluated in an uncontrolled study for  SARS -
CoV-1 illness in Hong Kong. This was shown to be more effective when given early, 
and in those who were polymerase chain reaction ( PCR ) positive and serone gative.47  
In a pilot uncontrolled study of CCP in China, one dose of 200  milliliters ( mL) of CCP 
with neutralizing antibody titers  ≥ 1:640 dilution was used in 10 patients with severe 
COVID -19.48 This was shown to be safe and showed a possible improvement in 
clinical outcomes. Another study in New York reported that 39 patients given 
convalescent plasma had improvements in supplemental oxygen requirements and 
survival compared to retrospectively  matched controls.49  An initial report of the first  
5,000  hospitalized patients with COVID -19 given convalescent plasma through an 
expanded access program  in the US reported that SAEs  within 4 hours of infusion 
occurred in less than 1% of patients.50  This study was not controlled.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
16 
 2.2.8  Hyperimmune Intravenous I mmunoglobulin (hIVIG)  
Anti-Coronavirus H yperimmune IVIG contains polyvalent antibodies with  neutralizing 
specificity for SARS -CoV-2. It has  the potential to  provide a standardi zed therap y to 
augment host immunity to SARS -CoV-2 and  prevent disease progression in 
symptomatic patients . Hyperimmune IVIG differs from standard IVIG in its derivation 
from donors who have mounted an immune response to the infection of interest 
(natural infection  as undertaken in this protocol,  or following  vaccination for other 
disease states ), and its standardization as a product based on neutralizing antibody 
titers  or similar assays demonstrating its activity against the infection of interest. 
Hyperimmune globulin requires plasma from otherwise healthy i ndividuals in the 
convalescent phase of the infection, and it is clear that there will be many individuals 
fitting this criterion with most patients recovering  from COVID -19 and therefore able 
to safely provide a plasma donation  during convalescence . There fore, this resource 
will be rapidly available and will serve as an accessible therapeutic modality across 
multiple jurisdictions  globally . 
In other respects, hyperimmune and standard IVIG have similarities in their 
production, constituents, and safety prof iles. Production of IVIG requires care when 
selecting donors, optimum screening of collected products for known infective agents, 
use of virus inactivation methods like fractionation, and physical and chemical 
treatment including solvent detergent treatmen t and caprylation (a short -chain 
saturated fatty acid which results in a product enriched for IgG) and nanofiltration .45 
Stabilizers currently used in IVIG are nonessential amino acids like glycine and L - 
proline unlike previous sucrose -containing preparations which could predispose to 
acute renal failure . 
Stand ard IVIG is by far the more widely used product compared with the various 
hyperimmune globulins, and contributes considerably to our understanding of the 
safety and administration  of hyperimmune IVIG. Standard IVIG became a 
commercially available product i n the early 1980s and remains an important 
therapeutic agent in those with primary immunodeficiencies, where it replaces absent 
or deficient immunoglobulins, and in immune thrombocytopenia and other 
autoimmune conditions, where it acts as an immunomodulato r.45 Collected from large 
pools of human plasma, polyvalent and highly diverse monomeric IgG is the key 
product constituent. Very low  levels of  other plasma constituents such as other 
immunoglobulins including IgA and IgM and possibly IgE, solubilized membrane 
components, complement proteins, coagulation factors, and possibly other solubilized 
receptors, as well as specific antibodies to human le ukocyte antigen ( HLA) 
determinants and lymphocyte surface molecules are also present, and in some 
circumstances may contribute to its mechanism of action.51  
Standard IVIG is currently being studied  as a therapy for COVID -19 illness  in small 
trials, primari ly as an immuno modulatory agent. For this purpose, it is  given at  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
17 
 relatively high doses (in the range of 2  grams ( g) per kilogram ( kg) divided over 4 to 5 
days ). Ongoing trials include [STUDY_ID_REMOVED] , [STUDY_ID_REMOVED] , and [STUDY_ID_REMOVED] . 
Some  efficacy for standard IVIG has also been reported in a retrospective 
comparison52 and a small case series .53 
Hyperimmune globulin preparations have been described to have therapeutic utility in 
varicella zoster, cytomegalovirus ( CMV ) pneumonitis,54 parvovirus induced red cell 
aplasia,55 and respiratory syncytial virus ( RSV) infection56 in patients  with underlying 
impairments of immunity . In addition, hyperimmune globulins  for hepatitis A,57 
hepatitis B,58 and rabies59 have proven prophylactic efficacy and their use is 
recommended in clinical guidelines. The potential utility of this approach has also 
been explored in  severe respiratory infections caused by other pathogens including 
influenza60 and severe acute respirato ry syndrome ( SARS ).61,62,63 However, the 
evidence for efficacy of hyperimmune globulin in SARS infection is limited because in 
that disease outbreak, its use was assessed only in small, poorly controlled clinical 
studies.64 
While there are some mechanistic similarities between hIVIG and convalescent 
plasma,65 individual doses of convalescent plasma are inherently variable from unit to 
unit. Unlike hIVIG, convalescent plasma  cannot be standardized as a therapeutic  
product at the required scale . In contrast to convalescent plasma where generally, a 
single unit of plasma obtained from a single ABO compatible donor is used, hIVIG is 
a highly purified preparation containing high titers  of neutralizing antibodies pooled 
from multiple d onors, and would be safer and have higher activity than CCP. 
Regulatory compliance and availability of assays to detect SARS -CoV-2 in serum and 
virologic  assays to measure viral neutralization are critical.  
2.2.9  Study Treatments  
Anti-Coron avirus Hyperimmune Int ravenous Immunoglobulin ( hIVIG ) 
Anti-Corona virus hIVIG  is a human hyperimmune product of the purified gamma 
globulin (IgG) fraction of human plasma containing polyvalent neutralizing antibodies 
to SARS -CoV-2. hIVIG  is prepared from pooled plasma collected from healthy, adult 
donors who have recovered from SARS -CoV-2 infectio n.   
Multiple hIVIG product s will be used in this trial . These hIVIG products are described 
below.  Each hIVIG is labelled with the following nam e: “Anti -COVID -19 Hyperimmune 
Globulin (Human)”. An aliquot from each lot of hIVIG prepared for this trial will also be 
tested centrally at the NIAID Integrated Research Facility at Fort Detrick, Maryland. 
This batched central testing will not form part of  the release criteria for hIVIG lots.   
The test results for each lot will be used in efficacy subgroup analyses by lot.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
18 
 Emergent BioSolutions  
Emergent BioSolutions ’ Anti-Coronavirus disease hIVIG, is a  liquid product contain ing 
approximately 100 mg/mL (10g%) protein of which at least 96% is purified human 
IgG, stabilized with 250 m illimoles (mmol)  proline and 0.03% PS80 at pH 5. 8. The 
vialed product will be clear to slightly opalescent, and colorless or pale -yellow liquid, 
essen tially free of foreign particles.  
The manufacturing process for SARS -CoV-2 hIVIG  contains two steps implemented 
specifically for virus clearance. The solvent and detergent step (using TnBP and TX -
100, respectively) is effective in the inactivation of enve loped viruses such as HBV, 
HCV, and HIV . Virus filtration, using a Planova™ 20N virus filter, is effective for the 
removal of viruses based on their size, including some non -enveloped viruses. These 
two viral clearance steps are designed to increase produc t safety by reducing the risk 
of transmission of enveloped and non -enveloped viruses. In addition to these two 
specific steps, the process of anion exchange chromatography was identified as 
contributing to the overall viral clearance capacity for small non -lipid enveloped 
viruses.  
Grifols Therapeutics , Inc.  
Grifols Therapeutics’ Anti -Coronavirus hIVIG is a ready -to-use sterile, preservative -, 
pyrogen -, and latex -free solution of human immune globulin for IV administration. The 
drug product consists of approximately 100 mg/mL ( 9.0 to 11.0% ) protein in 0.16 to 
0.24 M glycine. The pH of the drug product is 4.0 to 4.5 and the osmolality is close to 
the physiologic range. The protein composition consists of not less than 98% purified 
IgG. The product is clea r to opalescent and colorless to pale yellow liquid.  
The purification process used to manufacture hIVIG includes multiple segments with 
virus clearance capacity, such as caprylate -induced precipitation followed by filtration, 
caprylate incubation, ion -exch ange chromatography, 35 nanometers ( nm) 
nanofiltration, and low pH incubation. The capacity of these manufacturing segments 
to inactivate and/or remove virus was assessed via laboratory experiments in which a 
test virus was spiked into starting material th at was then processed comparably to the 
commercial scale by means of a small -scale model, and the processed material was 
assayed for residual viral infectivity. The purification process demonstrated a large 
overall virus clearance capacity for enveloped an d non -enveloped viruses of diverse 
physico -chemical properties, providing a very high margin of safety from the risk of 
transmission of infectious viruses.  
Takeda Pharmaceuticals  
Takeda’s anti -COVID -19 Hyperimmune Globulin (Human) is a ready -for-use steril e, 
liquid preparation of highly purified and concentrated IgG antibodies. The product 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
19 
 contains 100  mg/mL protein of which at least 98% is IgG; average IgA concentration 
is 37 micrograms ( µg)/mL and IgM is present in trace amounts. Glycine (0.25 M) 
serves as a stabilizing and buffering agent. There is no added sugar, sodium, or 
preservatives. The pH is 4.6 to 5.1; the osmolality is 240 to 300 mOsmol/kg. Only 
clear or slightly opalescent and pa le yellow solutions may be administered. Vials 
found to contain particles or discoloration must not be used.  
 The manufacturing process for anti -COVID -19 Hyperimmune Globulin (Human) 
contains three dedicated virus clearance steps, i.e., S/D treatment ,66,67 nanofiltration 
(35 nm) ,68,69 and low pH incubation at elevated temperature .70,71 Viral safety studies 
used virus models and target viruses to evaluate the clearance of lipid enveloped and 
nonenveloped deoxyribonucleic acid ( DNA ) and RNA viruses by the manufact uring 
steps specific for viral reduction. These studies demonstrated that the 3 dedicated 
virus inactivation/removal steps provide effective and robust clearance of HIV, West 
Nile virus ( WNV ), hepatitis A virus ( HAV), parvovirus B19  (B19V ), as well as of m odel 
viruses for HCV, HBV, HAV, and B19V.  
  CSL Behring  
Anti-COVID -19 hyperimmune globulin comes as a ready -for-use sterile, 10% protein 
liquid preparation in single -use vials. It contains 100 mg/mL protein stabilized with 
250 mmol/L L -proline. Anti -COVID -19 hyperimmune globulin has an osmolality of 320 
mOsmol/kg (range: 240 to 440 mOsmol/kg) and a pH of 4.8 (range: 4.6 to 5.0), with 
an IgG purity ≥ 98%.  The vialed solution is clear or slightly opal escent and colorless 
to pale yellow.  
Production of Anti -COVID -19 hyperimmune globulin requires sourcing plasma from 
convalescent  donors collected at qualified plasma collection centers, optimum 
screening of collected products for known infective agents, an d use of virus reduction 
methods like low pH incubation, clarifying depth filtration,  and 20  nm nanofiltration, 
which demonstrated a large overall virus clearance capacity for enveloped and non -
enveloped viruses of diverse physico -chemical properties. Stab ilizers currently used 
in IVIG are nonessential amino acids like L -proline unlike sucrose -containing 
preparations which could predispose to acute renal failure.  
Placebo  
Participants assigned to the placebo group for hIVIG will be given infusions of  a 
commercially available isotonic saline solution . There are color  differences between 
the infusion preparations for hIVIG and placebo.  Therefore, site pharmacists will be 
instructed to place a colored  sleeve or other suitable covering over all infusion bag s 
to mask the color of the contents  and reduce the risk of unblinding . The volume used 
for hIVIG and for placebo will be comparable.   
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
20 
  RISK/BENEFIT ASSESSM ENT 3
 Known Potential Risks  3.1
Potential risks of participating in this trial are those associated with havi ng blood 
drawn, IV catheterization, possible reactions to hIVIG infusions , thrombosis, the 
volume of fluid infused, and breach of confidentiality.  These risks are discussed 
below.  
3.1.1  Blood Draw and IV Catheterization  
Drawing blood may cause transient discomfort and fainting. Fainting is usually 
transient and managed by having the participant  lie down and elevate his/her legs. 
Bruising at the blood collection sites may occur but can be prevented or lessened by 
applying pressure to the blood draw site for a few minutes after the blood is taken. IV 
catheterization may cause insertion site pain, phlebitis, hematoma formation, and 
infusate extravasation; less frequent but significant complications include 
bloodstream and loc al infections. The use of aseptic (sterile) technique will make 
infection at the site of blood draw  or at catheter ization  less likely.  
3.1.2  Study Treatments  
The hIVIG used in this study is manufactured in the same manner and to the same 
standards as commerciall y available IVIG. This includes screening for blood borne 
pathogens, and manufacturing steps including solvent/detergent to inactivate any 
viruses. The risks are anticipated to be the risks of standard IVIG preparations. 
Specific considerations related to the use of hIVIG in COVID -19, including thrombosis 
and the theoretical risk of antibody -dependent enhancement, are summarized at the 
conclusion of this section.  
As IVIG is made from human plasma, transmittable viral infections like hepatitis B, 
hepatitis C , and human immunodeficiency virus (HIV) are a potential risk (though 
steps are taken to screen for and inactivate such pathogens). In addition, there is a 
theoretical risk, although  deemed very low, that hIVIG administration may be capable 
of transmitting  other known or unknown infectious agents other than viruses, such as 
infectious prions (e.g., the agent of Creutzfeldt -Jakob disease).  
Immune globulin administration may impair the efficacy of live attenuated virus 
vaccines such as measles, rubella, mumps , and varicella.  
The safety of human IV immunoglobulins is well established.  As described in the 
Investigational Brochures (IBs), a  number of adverse events have been associated 
with the use of IVIG in both children and adults. In the range of 1 to 15%, usually less 
than 5% , of recipients experience some type of reaction, with the severity ranging 
from mild to severe. Most reactions occur during the initial 30 to 60 minutes of the 
infusion and are mild and self -limited.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
21 
 Pyrogenic Reactions  
• These react ions are marked by a significant rise in temperature and are usually 
accompanied by systemic symptoms.  
Allergic Reactions  
• Allergic reactions often present with an uncomfortable feeling, especially a 
tightening around the neck, chest, or abdomen. There may be difficulty 
swallowing, a choking sensation, or difficulty breathing. Other symptoms of 
anaphylaxis include wheezing, rash, hives, rapid or weak pulse, hypotension, 
sweating, or an upset stomach with or without nausea, vomiting or diarrhea. 
Other mor e serious allergic reactions are rare, and include hemolysis and 
aseptic meningitis.  
Vasomotor Symptoms  
• These can occur with or without additional cardiac manifestations.  
• Blood pressure can either increase or decrease, and may be accompanied by 
flush ing or tachycardia.  
• Patients experiencing such reactions may report shortness of breath or 
tightness in the chest.  
Non-allergic Systemic (Anaphylactoid) Reactions  
• These reactions most commonly include headache, dizziness, or 
lightheadedness.  
• Patie nts can also experience chills, nausea, vomiting, back or hip pain, 
malaise, myalgia and arthralgias.  
• Rigors are a rare infusion reaction that is an extreme form of chills that affects 
the whole body with vigorous shaking.  
• The most frequent cause of su ch reactions is infusion at an excessively rapid 
rate. 
• These types of reactions are more common in a patient naïve to IgG treatment 
and/or who harbor chronic infection. These reactions may be marked by 
flushing and warmth of the skin, chills, headache, d izziness, nausea, vomiting, 
and muscle aches.  
• Frequently the patient reports anxiety and in some cases, “a sense of 
impending doom.” Often, the patient will have elevated blood pressure rather 
than hypotension, distinguishing this type of reaction from t rue anaphylaxis.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
22 
 Post-infusion Reactions  
• These reactions can occur immediately or up to 48 to 72 hours following the 
infusion.  
• Symptoms associated with post -infusion reactions are usually less severe in 
nature, but can interfere with a patient’s qual ity of life.  
• Common post -infusion reactions may include headache, low -grade fever, 
nausea, arthralgias, and generalized malaise.  
Other Reactions  
• Renal dysfunction, acute renal failure, and osmotic nephropathy may occur with 
immune globulin intravenous products in predisposed patients. Renal 
dysfunction and acute failure occur more commonly in patients receiving IVIG 
products containing sucrose. The  hIVIG  products in this study do  not contain 
sucrose.  
• Transfusion -related acute lung injury (TRALI) , although very rare, may occur 
and is characterized by severe respiratory distress, pulmonary edema, 
hypoxemia, normal left ventricular function, and feve r. 
• The infused volumes of study product may be as high as 200  mL, so there is the 
risk of volume overload in the recipient which could cause pulmonary edema.  
Transfusion -associated circulatory overload (TACO) has been associated with 
plasma infusion and may be clinically indistinguishable from TRALI even though 
the physiologic mechanisms differ.  TACO is hydrostatic, not permeability, 
edema and more responsive to diuresis when it occurs.  Patients with pre -
existing conditions who may not tolerate th e volume  of hIVIG/pl acebo  to be 
given  will be excluded from this study, but this condition could still occur in 
recipients.  
• There are case reports of pulmonary emboli occurring after administration of 
IVIG and plasma therapy, though definitive studies assessing risk are lacking .72 
Pulmonary emboli have been shown to develop in approximately 10 -15% of 
critically ill adults.73 Other thrombotic events, including myocardial infarction, 
cerebral vascular accident, and deep vein thrombosis may also occur.  
Specific Consid erations in COVID -19 
There is potentially a slight elevation in the risk of thrombosis with standard IVIG 
therapy, and in some cases COVID -19 is associated with thrombotic complications. 
Hence participants with pre -existing prothrombotic tendencies will no t be included  
and any thrombotic events will form part of the primary endpoint assessment and be 
monitored during interim safety analyses  by the DSMB .  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
23 
 There is a theoretical risk the antibody infusion may worsen the disease course of 
COVID -19 via antigen -dependent enhancement (ADE). It is unclear if this 
phenomenon is relevant and clinically significant in COVID -19, but to ensure 
detection of any such phenomenon (which could be manifested by disease 
progression soon after hIVIG infusion) close monitoring of clinical disease outcomes 
will be maintained in the randomized group s, including in the days prior to the primary 
endpoint  assessment at Day 7 . 
3.1.3  Confidentiality and  Privacy  
Participants  will be asked to provide personal health information (PHI ). All attempts 
will be made to keep this PHI confidential within the limits of the law. However, there 
is a chance that unauthorized persons will see the participant’s  PHI. All source 
records including electronic data will be stored in secured systems in accordance with 
institutional policies and government regulations.  
All study data that leave the site (including any electronic transmission of data) will be 
identified only by a coded number that is linked to a participant  through a code key 
maintained a t the clinical site. Names or readily identifying information will not be 
released.  Electronic files will be password protected.  
Only people who are involved in the conduct, oversight, monitoring, or auditing of this 
trial will be allowed access to the PHI  that is collected. Any publication from this trial 
will not use information that will identify study participants . Organizations that may 
inspect and/or copy research records maintained at the participating site for quality 
assurance and data analysis inc lude groups such as the IRB, NIAID and applicable 
regulatory agencies (e.g. US Food and Drug Administration [ FDA]).  
 Known Potential Benefits  3.2
While the trial is conducted to test the hypothesis that hIVIG will reduce the risk of 
further disease progression , hIVIG may or may not prevent  this outcome in any 
individual who participates in this trial.  However, there is benefit to society from their 
participation in this trial resulting from insights gained about the therapeutic agent 
under study as well as the natural history of the disease. While there may not be 
benefits for an individual, there will be benefits to society if a safe, efficacious 
therapeutic agent can be identified during this global COVID -19 outbreak.  
 OBJECTIVES AND ENDPO INTS  4
 Primary  Objective s and Primary Endpoint  4.1
The primary objective  is to compare the clinical status of participants in the hIVIG + 
SOC and placebo + SOC groups on Day 7 using an ordinal outcome with 7 mutually 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
24 
 exclusive categories. On Day 7, the worst of the 7 categories the p articipant was in 
that day will constitute the primary outcome. The 7 categories are:  
7. Death  
6. End-organ failure  
5. Life-threatening end -organ dysfunction  
4. Serious end -organ dysfunction  
3. Moderate end -organ dysfunction  
2. Limiting symptoms due to COVID -19  
1. No limiting symptoms due to COVID -19 
Appendix F  provides clinical definitions of each category. In addition to the overall 
summary odds ratio (OR) that will be estimated as described in Section 11.1, ORs 
will be estimated for the 6 dichotomized definitions of improvement that can be 
formulated from the categories of the ordinal outcome.  
4.1.1  Rationale for Primary Endpoint  at Day 7   
The goals of this study are to assess the safety, tolerability and efficacy of a single 
infusion of hIVIG in preventing further progression and mortality related to COVID -19 
when administered at the onset of clinical progression, with the aim o f improving  the 
long term outcome of the disease process. There is as yet no consensus on the 
optimal endpoint for determining clinical benefit from COVID -19 therapies, including 
the constituent elements of the endpoint and the timing of its assessment aft er 
randomization. Both may differ depending on the target population and the nature of 
the treatment studied.  
The primary ordinal outcome captures the range of severity experienced by 
hospitalized patients with COVID 19, recognizing that end -organ manifest ations in 
addition to pneumonia and ARDS are increasingly emerging as significant 
contributors to morbidity. The ordinal outcome includes 7 well -defined mutually 
exclusive categories that assess further progression of disease as well as recovery 
from COVID -19.  
The ordinal outcome includes both pulmonary manifestations as assessed in prior 
COVID -19 trials and additional components representing key non -pulmonary 
outcomes; the latter are highlighted as “extra -pulmonary”  in the guidance table 
(Appendix F ). The primary endpoint will include both pulmonary and extra -pulmonary 
components, while the pulmonary manifestation scale only will be reported as a 
secondary endpoint.  
Day 7 was chosen for the timing of the primary endp oint for several reasons based 
on the following assumptions. The impact of hIVIG on disease progression may not 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
25 
 be immediate; a few days may be needed to see the effects on clinical outcomes as 
measured by the ordinal outcome. Also, transient treatment eff ects that are no  longer  
present at Day 7 may be clinically less relevant . Assessment of the ordinal outcome 
at a later time point  may result in a diminished treatment difference because 
spontaneous recovery from COVID -19 may have begun in many participants . Also, 
antibody differences between the treatment groups, an important biologic mechanism 
for observing a clinical benefit, are assumed to  be greatest during the first week after 
infusion.  
Lastly, use of Day 7 to characterize the clinical severity of par ticipants in 7 categories 
as studied here, results in a distribution of participants in the placebo group for the 
ordinal outcome that is sufficiently granular and not overly skewed to the most severe 
or least severe categories and, therefore, provides goo d power for comparing the two 
treatment groups with a feasible sample size given the difficulty in producing large 
quantities of hIVIG (see Section 5.5).  
 Secondary Objectives  4.2
Secondary objectives will be assessed by comparing hIVIG + SOC with placebo + 
SOC over the 28 day follow -up period for outcomes listed below.  Because there is no 
established endpoint for evaluating the clinical efficacy of treatments for COVID -19, 
other clinically relevant outcomes, including outcomes used in other COVID -19 
treatment trials, will be recorded. Thus, the randomized groups can be compared for 
multiple outcomes, and results can be compared or combined with other trials. Many 
of the e ndpoints used in other trials are ordinal outcomes or are defined based on a 
dichotomy of an ordinal outcome and assessed at a single follow -up time point or as 
a time -to-event outcome.  
1. All-cause mortality through Day 28.  
 
2. The primary ordinal outcome on Da ys 3, 5, 14 and 28.  
 
3. Change in National Early Warning Score (NEWS)  (see Appendix G ) from baseline 
at Day 3. 
 
4. Time to the 3 least favorable categories of the primary outcome measure.  
 
5. Time to the 2 most favorable categories o f the primary outcome measure . 
 
6. Hospitalization  status ( a binary outcome, alive and discharged from the hospital to 
home or rehabilitation  versus dead or hospitalized ) at Days 7, 14 and 28.  
 
7. Time to discharge  (this is similar to the recovery ou tcome  used in the ACTT -1 
trial40)   
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
26 
  
8. Days alive outside of a hospital through Day 28  
 
9. Pulmonary only components of the primary outcome measure  at Days 3, 5, 7, 14 
and 28  
 
10. Thrombotic components of the primary outcome measure ( stroke, myocardial 
infarction , venous and arterial thrombosis or embolism , plus disseminated 
intravascular coagulation ) at Days 3, 5, 7, 14, and 28 .   
 
11. Outcomes assessed in other treatment trials of COVID -19 for hospitalized 
participants in order to facilitate cross trial comparisons and overviews, e.g., 6 -, 7- 
and 8 - category ordinal scales  at days 7, 14 and 28 ; and binary outcomes defined 
by improvement or worsening based on the primary ordinal outcome and ordinal 
outcomes used in other trials.  
 
12. Clinical organ dysfunction defined by new onset  of any one or more of the 
following conditions (or requirement for the following therapies) through Day 28:  
a. Respiratory:  
1. Extracorporeal membrane oxygenation (ECMO)  
2. Invasive ventilation  
3. Non-invasive ventilation or high flow oxygen  
b. Cardiac and vascular:  
1. Myocardial infarction  
2. Myocarditis or pericardi tis  
3. NYHA Class III/IV congestive cardiac failure  
4. Vasopressor therapy  
c. Renal:  
1. Renal replacement therapy  (dialysis)  
d. Hepatic:  
1. Hepatic decompensation  
e. Neurological  
1. Cerebrovascular event ( stroke)  
2. Encephalitis, meningitis or myelitis  
3. Acute delirium  
f. Hematological:  
1. Disseminated intravascular coagulation  
2. New thrombotic events, including pulmonary embolism , deep venous 
thrombosis, or arterial thrombosis  
g. Infec tive: 
1. Microbiologically -proven severe infection (not including SARS -CoV-
2) 
 
13. Safety and tolerability will be assessed using outcomes described above (e.g., 
mortality and thrombotic outcomes) and also assessed  by the following outcomes : 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
27 
  
a. A composite of incident grade 3  and 4 events  (not limited to a laboratory 
abnormality) , SAEs (see Section 10.1.2 ), or death through Day 7 (primary 
safety endpoint)  
b. Infusion reaction s of any grade severity during the infusion and 2 hours 
post-infusion, and percentage of participants for whom the infusion was 
interrupted or stopped prior to completion  
c. SAEs or deaths through Day  28 
d. Prevalence of adverse events of any grade on Day s 1, 3, 7 and 28 . 
 
14. Change in immunoglobulin levels (IgG, IgG subclasses,  IgM, IgA) and neutralizing 
antibody titers from baseline to Days 1, 2, 3, 7, 28 and 90.  
 
15. The primary endpoint by duration of symptoms  at study entry . This  is a key 
subgroup  analysis .  For th ose with shorter duration of time since symptom onset, 
the treatment effect is hypothesized to be greater than among p articipants who 
have had symptoms for a longer period of time.  This hypothesis assumes that 
disease progression among those with longer duration of symptoms at study entry  
will be primarily determined by organ damage that has already occurred instead of 
ongoing viral  replication.   In addition, it is assumed that  the natural antibody 
response to SARS -CoV-2 infection is likely to be greater at entry for those with 
longer symptom duration, and this would diminish the treatment difference 
between the hIVIG and placebo gro ups over the week following infusion.  Given 
the inclusion criteria of ≤ 12 days, we anticipate the upper quartile will be 8 -10 
days  (75% of participants will have symptom duration < 8 to 10 days).   In ACCT -1, 
a more severely ill target population than stud ied here, there was no limit to the 
duration of symptoms and the median was 9 days (interquartile range, 6 to 12).40   
The quartile definitions  for duration of symptoms will be de termined  following the 
completion of enrollment , and will be stated in the data analysis plan.    
 
16. The primary endpoint for other subgroups defined by the characteristics measured 
at baseline  will also be assessed : 
 Age 
 Biological sex  
 Race/ethnicity  
 BMI 
 Presence of selected chronic medical conditions (cardiovascular disease, 
diabetes, asthma, chronic obstructive pulmonary disease, hypertension, 
cancer)  
 Geographic location  
 hIVIG product  administered  
 hIVIG lot potency of ad ministered product  
 Upper respiratory SARS -CoV-2 viral load  
 Neutralizing antibody level  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
28 
  Oxygen saturation level  
 Dyspnea severity  
 Organ/respiratory dysfunction category based on ordinal primary outcome  
 NEW S 
 Disease progression risk score (defined using pooled treatment groups 
with the following baseline predictors of the day 7 ordinal outcome: age, 
gender, duration of symptoms, oxygen saturation level, ordinal outcome 
category at entry, NEWS, and chronic health conditions).  
 STUDY DESIGN  5
 Overall Study Design 5.1
This study is an adaptive, randomized, double -blind, placebo -controlled trial to 
evaluate the safety , tolerability and efficacy of hIVIG in consenting hospitalized 
patients with COVID -19 who have had COVID -19 symptoms ≤ 12 days , and who do 
not have lif e-threatening organ dysfunction or organ failure . Remdesivir will be 
provided to pa rticipants  in both the hIVIG and placebo groups as SOC  unless 
contraindicated for an individual pa rticipant .   
Participants may co -enroll in INSIGHT observational studies (e .g. INSIGHT 004 
Genomics, FLU -003+) or have been previously enrolled in such studies prior to 
hospitalization (e.g. ICOS) . 
 Randomization  5.2
Randomization will be stratified by site pharmacy (clinical sites may share a 
pharmacy).  Participants will be randomized in a 1:1 ratio to receive a single infusion 
of hIVIG or placebo .  
Hyperimmune IVIG  will be manufactured by multiple  groups  and the specific hIVIG 
distributed to  each site will be determined in a way that considers factors dis cussed in 
Section 5.4. 
Within each stratum permuted block randomization will be used to generate treatment 
assignments.  
 Blinding  5.3
Hyperimmune IVIG or placebo  will be prepared by a pharmacist who is unblinded to 
the treatment assignment.   
Blinding of the participant and clinical staff will be achieved by placing a colored 
sleeve over the infusion bags used for  hIVIG and placebo.  Placebo will consist of 
normal saline.   
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
29 
 In the event that the blind is broken for safety r easons, this will be recorded,  and the 
protocol co-chair (s) will be notified.  In that situation, every attempt will be made to 
minimize the number of people unblinded.  
 Distribution of Anti -Coronavirus  hIVIG to Clinical Sites   5.4
It is critical to establish whether Anti-Coronavirus  hIVIG is safe and effective as 
rapidly as possible. To accomplish this, hIVIG will be manufactured for use in this trial 
by 3 different groups . Four hIVIG products, two produced by an Alliance of several  
companies including Takeda Pharmaceuticals and CSL Behring, and one  each  
produced by Emergent BioSolutions and Grifols Shared Services North America, Inc., 
will be used. No single group  can prepare sufficient quantity of hIVIG product to 
rapidly complete this trial.  Thus, for practical reasons, the  primary analysis (see 
Section 11.1) which compares the hIVIG and placebo groups on Day 7 for the 
primary ordinal endpoint will pool the outcome results for the 4 different hIVIG 
products and matching placebos.  
 
To simplify logistics related to the supply of hIVIG to clinical sites and to take 
advantage of the randomization,  which is stratified by site pharmacy, the same hIVIG 
product will be provided to a given site pharmacy for the duration of the trial  to the 
extent possible . This is illustrated in Figure 2 with an example that assumes that 
there are 24 site pharmacies and the supply of each of hIVIG product s will be the 
same . 
The site pharmacy allocation of hIVIG will take into account estimates of the number 
of pa rticipant  doses each manufacturer will provide and estimates of the number of 
participant s to be enrolled by sites using each site pharmacy (i.e., it may not be an 
equal number of site pharmacies or pa rticipants  for each hIVIG product).  
 
It is likely that the hIVIG provided by each manufacturer will be from more than one 
lot during the study.  For each individual pa rticipant , all hIVIG vials used will come 
from the same lot. This plan for distributing the hIVIG will simplify the tracking of lots 
used by each site pharmacy.  This plan also simplifies the pharmacy plans prepared 
for each site pharmacy.   
 
More generally, with this plan, one can consider this as parallel  multi -center trials of 
different hIVIG pr oducts for which planned analyses that compare the hIVIG and 
placebo groups for primary and secondary outcomes will be pooled across the hIVIG 
products used.  With such a plan, depending on the number of doses of each hIVIG 
product provided, there may be ad equate power to compare each hIVIG product with 
matching placebo for some outcomes other than the primary efficacy outcome, 
including potentially  change in anti -SARS -CoV-2 IgG levels from baseline ( Day 0), 
safety outcomes, such as  AEs and infusion interruptions, and selected secondary 
efficacy outcomes.  
 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
30 
 FIGURE 2. EXAMPLE OF ALLOCATION OF H IVIG  TO 24 SITE PHARMACIES  
 
 
 
 
 
 
 
 
 Sample Size Assumptions  5.5
5.5.1  Primary Analysis  
The planned sample size for the trial is 500 participants  (250 in each  group). The 
following assumptions were made in estimating the required sample size. 
a. The primary analysis will be intention to treat.   
b. A proportional odds model with indicators for the six cut -offs corresponding to 
using any of categories 1 to 6 as cut -offs for determining clinical improvement, 
treatment group (hIVIG versus placebo) , baseline severity of illness as defined by 
the ordinal outcome , two -way interactions between baseline severity of illness and 
the six cut -offs, hIVIG product/matching placebo  used , and two -way interactions 
between hIVIG product/matching placebo used  and t he six cut -offs will be used to 
estimate the OR.   
c. Type 1 error = 0.05 (2 -sided) and power = 0.80.  
d. The clinical status (% distribution) of pa rticipants  in the placebo group at Day 7 is 
assumed as shown in the 3rd column in Table 1. Since both randomized treatment 
groups will receive remdesivir as SOC (unless contraindicated), these 
percentages were estimated using  Day 7 data from the ACTT -1 trial for a 
subgroup of patients similar to ours (the subgroup of participants who entered 
ACTT -1 in categories 4+5 of t heir 8 -category  ordinal outcome for disease severity  
and were randomized to the remdesivir  group ). 
e. We assumed an OR (hIVIG/placebo) of 1.61 for a more favorable outcome.  This 
corresponds to the % distribution of the clinical status of pa rticipants  in the hIVIG 
group at Day 7 shown in the 2nd column in Table 1 below.  For example, the 
percentage of pa rticipants  in the 2 most favorable categories wou ld be increased 
to 65.4% in the hIVIG group from 54.0% in the placebo group (a n 11.4% increase 
from the placebo group).  Conversely, the percentage of participants in the 4 most 
severe categories would decrease to 19.4% from 28.1% in the placebo group. 
The same proportional improvement was assumed across the ordinal scale.  
f. Sample size depends on a number of assumptions, including the hypothesized 
odds ratio, the number of categories in the ordinal outcome, and the distribution of  
responses for the placebo group.74 Hypothesized odds ratios closer to 1.0 
correspond to a smaller treatment effect, and require a larger sample size to 
Pharmacies  
1-6 
IVIG 1 
Placebo 1 
Pharmacie s 
19-24 
Placebo 4 
 IVIG 4 
Pharmacies  
7-12 
IVIG 2 
Placebo 2 
Pharmacies  
13-18 
IVIG 3 
Placebo 3 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
31 
 maintain 80% power.  The final sample size was chosen after consideration of a  
range of odds ratios and of category percentages for the placebo group.  
g. Based on the category percentages in Table 1, the estimated sample size is 494.  
This was increased to  500 to allow for a small number of participants who may be 
randomized but not receive the study infusion o r be lost to follow -up.  
We are plann ing a blinded  sample size re -estimation using pooled data (both the 
hIVIG and placebo groups combined) for the primary endpoint that will be made after 
approximately 150 participants  have completed the Day 7 follow -up assessment . The 
goal of the re -estimation is to retain 80% power to detect the hypothesized summary 
odds ratio of 1.61. The re -estimation will use the observed (pooled) distribution of the 
ordinal outcome at day 7, pooled across study arms.  
TABLE 1. HYPOTHESIZED PERCENTA GE OF PARTICIPANTS I N EACH CATEGORY ON DAY 7 IN 
THE H IVIG  AND PLACEBO GROUPS B ASED ON AFOREMENTION ED ASSUMPTIONS  
Category  hIVIG + SOC 
Group  Placebo + SOC 
Group  
7. Death  0.6 1.0 
6. End-organ failure  4.0 6.3 
5. Life-threatening end -organ 
dysfunction  4.2 6.3 
4. Serious end -organ dysfunction  10.6 14.5 
3. Moderate end -organ dysfunction .  15.1 17.9 
2. Limiting  symptoms due to  COVID -
19 57.6 49.0 
1. No limiting symptoms due to 
COVID -19 7.8 5.0 
Total  100.0  100.0  
 
5.5.2  Key subgroup analysis  
For the key subgroup defined according to duration of symptoms at entry, 375 
participants will be in the lower 3 quartiles.  Assuming the category percentages in 
Table 1 , with 375 participants, an OR of a more favorable outcome on hIVIG 
compared to placebo of 1.61 can be detected with 70% power .  For this subgroup, a n 
OR of 1.73 can be detected with 80% power and type 1 error =  0.05 (2 -sided).  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
32 
 5.5.3  Key secondary outcomes   
The study is not powered to detect treatment differences in mortal ity, because the 
mortality is expected to be low given the eligibility criteria.  
The following outcomes are defined as key secondary outcomes:   
Composite of death, end -organ failure , or life -threatening end -organ 
dysfunction  (categories 5 -7 of the ordinal outcome)  at Day 7 :  This composite 
outcome comprises the most severe three categories of the ordinal outcome . 
Decreasing the probability that a pa rticipant  enters one of these disease states and 
remains there  through Day 7, has high clinical significance.  Comparing the 
hIVIG +SOC  versus the placebo+SOC groups for the proportion of participants in the 
three worst categories on Day 7, a total sample size of 500 participants is sufficient to 
detect a decrease to  6.1%  in the hIVI G group compared with 13.6%  in the placebo 
group (difference  7.5%, OR= 2.4) with 80% power, under the following assumptions:  
a. The analysis will be intention to treat.   
b. Type 1 error = 0.05 (2 -sided) and power = 0.80.  
c. The proportion of participants who are in categories 5 -7 of the ordinal outcome on 
Day 7 in the placebo + SOC group is 13.6% (Table 1) .  In the ACTT -1 study, the 
proportion was 10.8%,  among participants in baseline categories 4+5 of the 
ACTT -1 ordinal outc ome who were randomized to the remdesivir group 
(confidential data, personal communication).   
A decrease from 13.6% to 8% (OR 1.8) could be detected with power of 47%. 
Time to discharge from hospital, time to the 2 most favorable categories of the 
primary ordinal o utcome : We expect that by Day 28, almost all participants will be 
discharged from the hospital .  Similarly, we expect most participants will  be in in one 
of the 2 most favorable categories of the primary ordinal outcome  by Day 28 . In the 
ACTT -1 trial, in the subset of par ticipants who entered the trial  with disease severity 
similar to o ur eligibility criteria  (ACTT-1 ordinal outcome categories 4+ 5), 94.7% had 
been discharged from the hospital by Day 28. This percentage was similar for the 
ACTT -1 definition of “recovery”  that include a small percentage of participants who 
were hospitalized but no longer requiring medical care . Comparing the hIVIG versus 
placebo groups for time to hospital discharge, our study is powered to detect a 
relative rate ra tio (RRR) of 1.3 with 80% power  and a significance level of 0.05.  The 
power calculations assume that the RRR is approximately constant to Day 28, the 
overall cumulative percentage discharged (pooled across treatment groups) by Day 
28 is 94% and that betwe en 2.5 and 3% withdraw consent or are lost to follow -up by 
Day 28.  We assume power is similar for time to the 2 most favorable outcomes of 
the primary ordinal outcome.    
Hospital ization  status : Comparing the hIVIG versus the placebo+SOC groups for 
the hospitalization  status (a binary outcome, alive and discharged from the hospital to 
home or rehabilitation versus dead or hospitalized ) on Day 7, the total sample size of 
500 participants is sufficient to detect a n increase in the proportion discharged  to 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
33 
 58% in the hIVIG group from 45% in the placebo group ( OR=1.7), with 80% power.  
Similarly, the study has 80% power to detect an increase to 81% in the hIVIG group 
compared with 70% in the placebo group ( OR=1.85) at Day 14 .  Corresponding 
estimates from the  ACTT -1 trial were 51%  discharged on Day 7, and  77% on Day 14 , 
for participants that were similar to ours and randomized to the remdesivir arm 
(confidential data; personal communication).  Our hypothesized percentages are 
slightly lower, because our eligib ility criteria allow for use of high -flow oxygen , in 
addition to the ACTT -1 ordinal categories 4 +5. Power calculations assume that the 
treatment groups are compared by intent -to-treat.  
 Schedule of Assessments  5.6
Participants will be randomized and given their infusion of study drug/placebo on Day 
0, in addition to standard of care therapy . All participants will be followed through  28 
days.  Consenting participants at selected sites will return for a  visit 90 days a fter 
randomization to obtain a blood draw ; this subset will comprise all participants at 
selected sites where return for a later visit is practical for participants . While in the 
hospital , evaluations will be made each day  (Appendix B ). SAEs and deaths should 
be immediately reported.  Participants  who are discharged will be asked to retu rn to 
the site at Day 1, 2, 3, 7 and Day 28 (if already discharged)  for a blood draw and 
health status assessment.   Additional visits after discharge at Days 5 and 14 can be 
completed by telephone contact.  
 Approach to Intercurrent Therapies and Clinical Trial Co - 5.7
enrol lment  
In general, the study will take a pragmatic approach to the use of intercurrent, 
concomitant med ications.  With the exception of convalescent plasma or IVIG 
(hyperimmune or standard, other than study drug) which is not permitted prior to entry 
or through Day 7, there are few restrictions.  
Participants will be asked at screening to agree to refrain fr om participation in other 
clinical trials until after the assessment of the primary endpoint (Day 7). However,  it is 
recognised that, in the case of progression to life -threatening disease and end -organ 
failure (broadly categories 5 and 6 of the outcome me asure) there will be 
considerable clinical concern, and participation in an additional clinical trial at that 
time will not be restricted.   
Prior participation in clinical trials (except receipt of IVIG, h IVIG or convalescent 
plasma) is not restricted, recognising for example that participants may have enrolled 
in a study for mild disease prior to progression and then may wish to participate in 
this study at the onset of progression.  
The planned analyses are by  intention to treat.  All pa rticipants  will be compared at 
Day 7 irrespective of use of concomitant treatments.  Concomitant treatments at 
baseline and Day 7 will be recorded. The study randomization and site stratification 
will balance the use of concomitan t medications on average at baseline and these will 
be summarized with other baseline characteristics.  Follow -up use of concomitant 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
34 
 treatments may differ by treatment group reflecting different efficacy/safety of the 
study treatments . Use of concomitant tr eatments will be summarized at Day  7 by 
treatment group.  
 SCIENTIFIC RATIONALE  FOR THE STUDY  6
The clinical course of SARS -CoV-2-infected individuals tends to diverge around day 3 
to 8, with a fraction of patients showing progression (most notably pneumonia) while 
others recover. A proportion of those progressing then further progress to end -organ 
failure, including respiratory failure, and in some cases death. Humoral immunity to 
SARS -CoV-2 is not yet well understood , and may be  variable or delayed in some  
individuals (including potentially those progressing) . Augmentation of the antibody 
response using passive immunotherapy with hIVIG to SARS -CoV-2 around  the onset 
of clinical progression  but before end -organ failure has developed may reduce the 
subsequent risk of further disease progression and death.   
 STUDY POPULATION  7
The total sample size is projected to be 500 adults ≥18 years of age with COVID -19 
and who meet all eligibility criteria . These participants will be enrolled at clinical trial 
sites globally.  Each site pharmacy may supply several clinical sites;  approximately 
20-30 site pharmacies  will participate (see Section 5.4). The estimated time from 
screening (Day -1 or Day 0) to the end of the study for an individual participant  is 
approximately 28 days.   Consenting participants at selected sites will return at Day 90 
for a final blood draw.  
Patient eligibility  must be confirm ed by a study clinician named on the delegation log. 
There is no exclusion for receipt of SARS -CoV-2 vaccine (experimental or licensed).  
 Inclusion Criteria  7.1
In order to be eligible to participate in this study, a pa rticipant  must meet all of the 
following c riteria : 
1. SARS -CoV-2 infection  documented by PCR  or other nucleic acid test (NAT) within 
3 days  prior to randomization OR documented by NAT more than 3 days prior to 
randomization AND progressive disease suggestive of ongoing SARS -CoV-2 
infection  
 
2. Symptomatic COVID -19 disease  
 
3. Duration of symptoms attributable to COVID -19 ≤ 12 days  
 
4. Requiring inpatient hospital medical care for clinical manifestations of COVID -19 
(admission for public health or quarantine only is not included)  
 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
35 
 5. Age ≥ 18 years  
 
6. Willingness to abstain from participation in other COVID -19 treatment trials until 
after study Day 7 
 
7. Provision of informed consent  by participant or legally authorized representative  
 
 Exclusion Criteria  7.2
1. Prior receipt of SARS -CoV-2 hIVIG or convalescent plasma from a person who 
recovered from COVID -19 at any time  
 
2. Prior receipt of standard IVIG (not hyperimmune to SARS -CoV-2) within 45 days  
 
3. Current o r predicted imminent (within 24 hours) requirement for any of the 
following:  
 
 Invasive ve ntilation  
 Non-invasive ventilation  
 Extracorporeal membrane oxygenation  
 Mechanical circulatory support  
 Continuous vasopressor therapy  
 
4. History of allergy to IVIG or plasma products  
 
5. History of selective IgA deficiency  with documented presence of anti -IgA 
antibodies  
 
6. Any m edical conditions for which receipt of the required volume of intravenous 
fluid may be dangerous to the patient  
 
 Includes New York Heart Association Class III or IV stage heart failure  
 
7. Any of the following thrombotic or procoagulant disorders : 
 Acute coronary syndromes, cerebrovascular syndromes and pulmonary or 
deep venous thrombosis within 28 days  of randomization  
 History of prothrombin gene mutation 20210, homozygous Factor V Leiden 
mutations, antithrombin III deficiency, protein C deficiency, protein S 
deficiency or antiphospholipid syndrome   
 
8. Any condition for which, in the opinion of the investigator, participation would not 
be in the best interest of the participant  or that could prevent, limit, or confound 
the protocol -specified assessments  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
36 
  Costs  to Pa rticipants  7.3
There is no cost to participants  for the research tests, procedures/evaluations , and 
study product while taking part in this trial.  Procedures and treatment for clinical care 
including costs associated with hospital stay may be billed to the participant , 
participant ’s insurance or third party.  
 STUDY PRODUCT  8
 hIVIG and Placebo  8.1
8.1.1  hIVIG Description  
Summary characteristics of the individual hIVIG products and placebo are 
summarized in Section  2.2.9 , with information on handling and preparation found in 
the Study Procedure Modules  
8.1.2  hIVIG Dose  
The hIVIG  product is administered as a single dose of 400 mg/kg (or 0 .4 g/kg) body 
weight, to a maximum dose of 40 g or 400 mL (i.e. capped at a body weight of 
100kg).  
The safety profile of hIVIG is anticipated to be comparable to licensed IVIGs for which 
dose s of well above 400 mg/kg are safe and well tolerated. Licensed IVIGs are used 
with doses up to 400mg/kg for immune replacement and up to 2 g/kg for 
immunomodulatory induction,  with an established favourable safety profile  in which 
adverse events are not closely dose related . 
The selected dose is derived from measures of anti -SARS -CoV-2 neutralizing 
potency  from hIVIG, in comparison with that observed in convalescent plasma pools. 
Convalesce nt plasma pools used to produce hIVIG contain approximately 10 mg/ mL 
of IgG immunoglobulin. Analysis of hIVIG shows an expected 10 -fold increase in anti -
SARS -CoV-2 binding IgG, but a lower than expected (5 -fold) enrichment in anti - 
SARS -CoV-2 neutralizing potency. This sugge sts that only 50% of anti -SARS -CoV-2 
neutralizi ng potency of plasma pools utilized to produce hIVIG is associated with 
IgGs. Based on this comparison , the neutralizing potency associated with the 
selected dose of 400 mg/kg hIVIG is significantly  higher than in  a fixed dose of  400 
mL of convalescent pla sma (3.5 -5 fold higher than that dose of plasma when  
administered to 70 -100 kg ). This dose was therefore selected as providing an 
appreciable dose margin over convalescent plasma (in addition to the other 
advantages of hIVIG  versus plasma), while remaining well within the accepted safe 
dose range for other IVIG products , and observing the limitations of hIVIG product 
supply.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
37 
 There are no data so far to define target therapeutic titers for anti -SARS -CoV-2 
antibody  which would support dose derivation from target titers rather than the 
approach to dose selection described above. Although not considered for dose 
selection in the present study, the hIVIG products ’ potencies , and circulating levels of 
immunoglobulins (IgG, IgG subcl asses, IgM, IgA) and neutralizing antibody titers 
following treatment will be measured. The analysis of the relationship between 
neutralizing titers and clinical outcomes may help to define a target therapeutic 
neutralizing titer for hIVIG+SOC and therefor e may support dose optimization for 
future clinical investigations.  
8.1.3  hIVIG Administration  
The hIVIG product is administered as a single dose of 400 mg/kg (or 0. 4 g/kg) current 
actual (not ideal) body weight, to a maximum dose of 40 g or 400 mL (i.e. capped at a 
body weight of 100  kg). The product as supplied should not be diluted. The infusion 
line may be flushed with normal saline.  
Infusion of hIVIG/placebo should commence at an infusion rate of 0.5 mg/kg/minute 
for approximately 30 minutes. If the infusio n is well tolerated, the rate of 
administration may be increased to a maximum of 4 mg/kg/minute as follows: the rate 
may be increased by doubling the infusion rate after intervals of not less than 30 
minutes, so long as the infusion remains well tolerated.  Participants should remain 
under close clinical observation  during the infusion and  for at least 60 minutes 
following completion of the infusion.  
For participants  judged to be at risk for volume overload  (including but not limited to 
those with pre-existing cardiac failure) , or who have for renal dysfunction  (estimated 
creatinine clearance < 60ml/min) , administer hIVIG at the minimum infusion rate 
practicable.   
For all participants, use of diuretics may be considered as clinically appropriate to 
avoid or t reat fluid overload, with the goal of maintaining participants in a euvolemic 
state following completion of the infusion.  
If adverse events occur, such as flushing, headache, nausea, changes in pulse rate 
or blood pressure, the rate of infusion should be s lowed or infusion should be 
temporarily stopped. When events resolve, the infusion may be resumed at a rate 
that is comfortable to the participant  (start at half of the last tolerated rate and 
increase gradually).  
The hIVIG  treatment should be immediately stopped should new onset or worsening 
of any of the following occur:  
• Profound hypotension (systolic blood pressure < 80 mmHg)  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
38 
 • Severe shortness of breath, wheezing, or sustained (i.e., ≥ 10 seconds)  new 
decrease in  oxygen  saturation  to < 90% on room air  
• Severe (Grade ≥ 3) local infusion site reactions, including pain, tenderness, 
erythema, or swelling as defined in the protocol -specified toxicity grading scale  
• Sustained body core temperature exceeding 38.5°C  or increas e in body core 
temperature > 2.0°C from baseline prior to infusion  
• Suspected intercurrent sepsis  (not manifestations of COVID -19) 
• Severe chest pain  
• Suspected anaphylaxis  
8.1.4  Preparation /Handling/Storage/Accountability  
This information is found in the Study Procedure Modules . 
 Remdesivir  Background Therapy  8.2
8.2.1  Rationale  
The antiviral drug remdesivir is being provided to all participants in this study, unless 
contraindicated.  Remdesivir was shown to improve time to recovery in moderately -
to-severely ill indi viduals hospitalized with COVID -1940.  It is being provided to 
standardize background therapy in this study ; while considered standard of care in 
hospitalized patients, due to shortages and regulatory status the drug may not be 
available at some participat ing sites during the study period.  
8.2.2  Description  
Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the 
intracellular delivery of a modified adenine nucleoside analog GS -441524. In addition 
to the active ingredient, the lyophilized formulation of remdesivir contains the 
following inactive ingredients: water for injection, sulfobutylether -β-cyclodextrin 
(SBECD ), and hydrochloric acid and/or sodium hydroxide.  
8.2.3  Administration  
Remdesivir will be administered as a 200 mg IV loading dose  (100 mL volume)  on the 
first day of  its infusion  followed by 100mg daily for the course described below; 
remdesivir may have commenced prior to randomization. For pa rticipants  starting 
remdesivir after randomization to hIVIG/placebo, t he loading dose should  be given 
immediately after the infusion of hIVIG/placebo , once any infusion reactions from that 
infusion have resolved ; for those who commenced remdesivir prior to randomization, 
the usual maintenance dose of 100 mg can be given after the hIVIG/placebo in fusion 
on Day 0  in the same manner . After the first remdesivir infusion,  a 100 mg once -daily 
IV maintenance dose (also 10 0 mL volume) is given each day while hospitalized for 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
39 
 up to a 10 day total course ; shorter durations of 5 days may be considered by the  
clinical investigator as appropriate in patients who are not ventilated . Infusions will not 
be given to participants after discharge.  The total treatment course should not exceed 
10 calendar days even if an infusion is missed.  
The dose should be given at approximately the same time each day (+/ - 2 hours for 
medication scheduling).  
Any dose that is delayed may be given later that calendar day. Any dose that is 
missed (not given that calendar day) is not made up. The treatment course continues 
as describe d above for hospitalized patients even if participants  become PCR 
negative.  
8.2.4  Contra indications  
Remdesivir is contraindicated in participants  with a history of hypersensitivity to 
remdesivir or any ingredient of the solution for injection .75 Clinical caution  should be 
exercised in individuals with hepatic or renal dysfunction, and hepatic and renal 
function should be checked prior to dosing  and monitored during therapy .75  
Remdesivir has not been studied in pregnancy, and use in pregnancy should be 
based on an individual assessment of risk/benefit by the treating physician.   
8.2.5  Dose Modification  
If the estimated g lomerular filtration rate ( eGFR ) decreases to < 25 m L/min, the 
remdesivir  infusion should not be given on that day. The infusion may be resumed on 
the next day if the eGFR returns to ≥ 30 m L/min. If the participant ’s renal function 
worsens to the point tha t they require hemodialysis or hemofiltration, remdesivir  will 
be discontinued.  
If the ALT and/or AST increases to > than 5 times the upper limit of normal, the dose 
of remdesivir should be withheld and not be restarted until the ALT and AST  reduces 
to ≤ 5 times the upper limit of normal.  
8.2.6  Preparation/Handling/Storage/Accountability  
This information is found in the Study Procedure Modules . 
 Standard of Care Therapy  8.3
8.3.1  Thromboprophylaxis  and diagnosis of thrombotic complications  
Consideration should be given to the use of pharmacological thromboprophylaxis 
(thrombosis prevention) in line with local clinical guidelines  as appropriate for an 
individual participant, in addition to approaches to maintain mobility and minimize 
other th rombotic risks . Standard approaches to thromboprophylaxis supported by 
high quality evidence include  the use of low molecular weight heparin (for example, 
enoxaparin 0.5m/kg daily ; high quality evidence) , which is the preferred agent in 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
40 
 some COVID -19 treat ment guidelines .76,77,78 However other standard approaches in 
accordance with local and institutional guidelines and the medical circumstances of 
an individual participant may also be considered, including the use of low 
(prophylactic) dose unfractionated heparin (high quality ev idence), or higher doses 
than prophylactic doses as judged appropriate (low quality evidence).  Specialist 
advice should be sought for participants who are pregnant.  
An appropriate degree of clinical suspicion should be maintained for the development 
of new  thrombotic complications, including deep venous thrombosis, pulmonary 
embolism, and other vascular events. Use of laboratory testing such as D -dimer may 
be confounded in the presence of acute COVID -19 infection. Consideration should be 
given to use of def initive imaging strategies for diagnosis wherever possible (for 
example, limb ultrasonography, computed tomography pulmonary angiograms), as 
appropriate for an individual participant.  
8.3.2  Other Standard Supportive Care  
Participants will be offered  supportive care of complications of COVID -19 as clinically 
appropriate for the individual.  
This includes appropriate management of pneumonia, hypoxemic respiratory 
failure/ARDS, sepsis and septic shock, cardiomyopathy and arrhythmia, acute kidney 
injury, and complic ations from prolonged hospitalization, including secondary 
bacterial infections, thromboembolism, gastrointestinal bleeding, and critical illness 
polyneuropathy/myopathy.  Such care  includes treatment with anti -bacterial agents for 
patients believed to have bacterial infection (high quality evidence), and guidelines -
compliant management of sepsis when it is present (moderate quality evidence).  
For participants requiring intensive care measures , consideration should be given to 
supportive care measures including lung-protective ventilation for patients who 
require invasive ventilation (high quality evidence) and prone positioning for 
mechanically ventilated patients with more than moderate ARDS (high quality 
evidence) .79,80 
As note d in section 8.1.3, hIVIG administration, use of diuretics may be considered 
as clinically appropriate to avoid or treat fluid overload.  
Links to details of such care can be found in Appendix D.   
8.3.3  Cautions and Contraindications  
It is not recommended to use high dose chloroquine (600 mg twice daily) due to 
studies showing excess harm and no demonstrable benefit. (Hydroxy)chloroquine 
has no documented clinical benefit, and hence should not be used as part of SOC  for 
COVID -19. Of note, the effectiveness of remdesivir may  also be reduced if combined 
with (hydroxy) chloroquine , and hence it is not advisable to combine these two drugs ; 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
41 
 in patients who are on pre -existing hydroxychloroquine for therapy of other diseases 
such as systemic lupus erythematosus , specialist advice should be sought .81  
8.3.4  Infection Control Measures  
Minimum standards of protection to reduce the risk of SARS -CoV-2 transmission  
from trial participants to research personnel, participants in other trials , or patients 
treated in the same facility  can be found in links displayed in Appendix D . 
 STUDY ASSESSMENTS AN D PROCEDURES  9
 Screening /Baseline , Follow -up and Endpoint  Assessments  9.1
Data collection at each visit is outline d below and summarized in Appendix B . Day 0 
refers to the day on which randomization occurs and on which the hIVIG/placebo 
infusion is given.  Screening and baseline assessments can be done on the same 
day.  The term “baseline” refers to data t hat are collected prior to randomization.  
9.1.1  Screening /Baseline Assessments  
After obtaining  informed consent, the following assessments are performed within 24 
hours  prior to randomization  to determine eligibility and to collect  baseline data : 
 Confirm EITHER:  
 -    the positive SARS -CoV-2 test result  (PCR or other NAT)  was performed within 
3 days prior to randomization or,  
- if more than 3 days prior to randomization, the prospective participant 
demonstrates progressive disease suggestive of ongoing SARS -CoV-2 
infection  
 Take a focused medical history , including the following information:  
− Demographics including age, biological sex 
− Day of onset of COVID -19 signs and symptoms  
− History of chronic medical conditions , including targeted conditions for 
outcome analys is  
− Medication allergies  
− Current use of targeted concomitant medications  
− Prior use of  monoclonal antibody treatment or SARS -CoV-2 vaccine trial 
participation  
 
 Perform a focused physical examination : 
− Height  and weight ;  
− Vital signs: Blood pressure, heart rate 
− Respiratory rate, oxygen requirements and saturation  
 
 Obtain blood for local laboratory evaluations:  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
42 
 − White blood cell count  
− Hemoglobin  
− Platelets  
− Lymphocytes  
− C-reactive protein ( CRP )  
− Serum creatinine  
− Alanine aminotransferase ( ALT) and/or aspartate aminotransferase ( AST) 
 
 Determine disease status at entry (includes SpO2, oxygen requirements) for the 
constituents of the ordinal outcome categories.  
 
 Plasma and serum specimens for central testing for immunoglobulin levels, SARS -
CoV-2 neutralizing antibody determination and storage for future  COVID -19 related 
research ( four [4]  1 mL aliquots of serum and four [4]  1 mL aliquots of plasma).  
Two 9mL tubes, SST and EDTA, of blood (18 mL total) will be drawn in order 
obtain the 8 aliquots.  
 
 Mid-turbinate swab for determination of SARS -CoV-2 viral load in central 
laboratory  
 Urine or serum pregnancy test (in women of childbearing potential)  (not an 
exclusion criterion but performed to ensure any pregnancy is recognized at entry)  
Note: If a woma n is either postmenopausal (i.e., is age ≥ 45 years and has had ≥12 
months of spontaneous amenorrhea) or surgically sterile (i.e., has had a 
hysterectomy, bilateral ovariectomy (oophorectomy), or bilateral tubal ligation), she is 
not considered to be of ch ildbearing potential.  
 
The overall eligibility of the patient for the s tudy will be assessed once all screening 
values are available. The screening process can be suspended prior to complete 
assessment at any time if exclusions are identified by the study  team.  
Participants  who qualify will be randomized  within 24 hours of obtaining the baseline 
assessments .  Post-randomization on Day 0 the following will be record ed: 
 Adverse events of any grade severity prior to starting the infusion  
 Start and stop times of the infusion of hIVIG/placebo and remdesivir  
 Infusion related reactions  
 Whether the completion of the infusion was as planned  
 Medication used prophylactically or therapeutically to manage infusion -
related reactions  
 Adverse events (AEs)  of any grade seve rity during and for 2 hours after the 
infusion  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
43 
 9.1.2  Follow -up assessments  
Participants will be followed through Day 28 following randomization for collection of 
study data. Clinical data  targeted to components of the primary and secondary 
endpoints  will be collected daily during hospitalization, and at scheduled visits to day 
28 after discharge. This will include discharge status, development of key medical 
conditions, vital signs including SpO 2. On Day 7, interim targeted physical exam  and 
concomit ant medication s will be collected  along with the results o f blood tests for 
serum creati nine, ALT or AST, white blood cell count , hemoglobin , platelets , 
lymphocytes , and C-reactive protein (CRP) .  
AEs of any grade severity will be collected on Day 0 prior to infusion and on Days  1, 
3, 7, and 28 (AEs present on those days).  Incident  AEs of grade 3 or 4 severity will 
be collected through Day 7 and all SAEs  will be collected through Day 28.  
The primary ordinal outcome measure will be assessed daily while the participant is 
hospitalized and on Day 3, 5, Day 7 (primary endpoint), Day 14 and Day 28  for all 
participants .  Items necessary for determination of NEW S will be collected on Day 3.  
The Borg dyspnea score will be evaluated at baseline and day 7. 
For participants who are no longer hospitalized, in-person visits will be done on study 
days where blood is collected (Days 1, 2, 3, 7, and 28).  For other visits  (Day 5 and 
Day 14) , contact with the participant for the purpose of study data collection may be 
performed by telephone , recognizing that certain components of the endpoints (e.g. 
SpO 2) are not likely available from outpatients. Other information as possible will be 
gathered .  
On Days 1, 2, 3, 7, and 28, plasma and serum samples  (four 1 mL aliquots  of both 
plasma and serum at each visit)  will be obtained for central testing of antibody levels  
(including neutralizing antibodies) to  SARS -CoV-2 and for storage for future related 
research.  Two 9  mL tubes, SST and EDTA, of blood (18 mL total) will be drawn in 
order obtain the 8 aliquots.  
In consenting participants at selected sites  (determined at site level prior to opening; 
selected  sites will en deavor to follow all participants to day 90) , plasma  and serum 
samples  (four 1 mL aliquots  of both plasma and serum ) will be obtained at Day 90 for 
central testing  of antibody levels  (including neutralizing antibodies) to SARS -CoV-2 
and for storage for future related research.  Two 9mL tubes, SST and EDTA, o f blood 
(18 mL total) will be drawn in order obtain the 8 aliquots.  
For patients co -enrolled on INSIGHT 004 Genomics, where genomics samples have 
not already been collected prior to enrollment in this protocol they may be collected at 
any time during follo w-up. 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
44 
 9.1.3  Stored Samples and Future Research  
The plasma and serum specimens collected as outlined above and the inoculum from 
the baseline mid -turbinate nasal swab will be stored at a central specimen repository 
in the US.  In addition to the specified testing  to be done per protocol, the specimens 
will be available for later use in research concerning COVID -19, SARS -CoV-2, and 
the impact of the study treatment.  Proposed research utilizing these specimens will 
be reviewed and approved by the trial oversight co mmittee.  Results of research tests 
on individual specimens will not be given to participants or their clinicians.  Aggregate 
research results will be made available.  
 SAFETY REPORTING  10
The safety evaluation of the study intervention includes several components, all of 
which will be regularly reviewed by the independent DSMB.  For this protocol, the 
term “study intervention” refers to the hIVIG /placebo and to remdesivir .  
With the excepti on of infusion related reactions of any grade, which are only collected  
for the hIVIG /placebo , all other AEs are collected  for the study intervention (either the 
hIVIG/placebo  or study -provided SOC treatment).   Selected events will be reported to 
regulator s and IRBs/ethics committees in addition to being regularly reviewed by the 
DSMB.  
The following information will be collected to evaluate safety:  
 Infusion -related reactions of any grade severity during and within 2 hours post -
infusio n of the hIVIG/placebo . 
 Clinical AEs of any grade severity will be collected on Days 0, 1, 3, 7, and 28 
(AEs present on those days).  
 Targeted laboratory abnormalities of any grade severity at Day 7. 
 Incident g rade 3 and 4 clinical adverse event s occurring through Day  7 
(isolated laboratory abnormalities that are not associated with signs or 
symptoms are not recorded) . 
 Clinical events that are collected as part of the primary  ordinal outcome or as 
secondary outcomes through  Day 28. These are protocol exempt events and 
are not reported as SAEs unless they are considered as related to the study 
intervention.  
 Serious adverse events , including laboratory -only serious events,  considered 
related to the study intervention (either the hIVIG/placebo  or a study -provided 
SOC treatme nt) through Day  28. 
 Serious adverse events that are not collected as part of the primary  ordinal 
outcome or as a secondary outcome through Day 28.   
 Unanticipated problems through Day 28. 
 Deaths through Day 28.  
An overview of safety data collected during the study is given in Table 2.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
45 
 Table 2.  Adverse Event Data Collection Overview   
 Day 0*  Infusion 
+2 hrs Day 
1 Day 3  Day 5  Day 7  Day 
14 Day 
28 
Infusion -related  
reactions and 
symptoms   X       
Incident Grade 3 and 4 
clinical AEs* * Collected through day 7  
 
Clinical AEs of any 
grade severity  X X X X  X  X 
Targeted laboratory 
abnormalities of any 
grade       X   
Targeted clinical events 
collected as study 
endpoints** *  Collected through Day 28  
Serious clinical AEs 
not reported as a study 
endpoint** *  Collected through Day 28  
Unanticipated 
problems   Collected through Day 28  
Any serious adverse 
event related to study -
provided treatment   Collected through Day 28  
 * pre -infusion  AE collection  
** Incident g rade 3 and 4 AEs are new (not present at baseline) AEs or AEs  that have 
increased in grade  
*** see section 10.2.5  for specific events  
 
Definitions and methods of reporting each type of event are given below.  
 Definitions  10.1
10.1.1  Adverse Event  (AE) 
An adverse event is any untoward or unfavorable medical occurrence  in a study 
participant, including any abnormal sign (e.g., abnormal physical exam or laboratory 
finding), symptom, or disease, temporally associated with their participation in 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
46 
 research, whether or not considered related to the research.  If a diagnosis is  clinically 
evident (or subsequently determined), the diagnosis, rather than the individual signs 
and symptoms or lab abnormalities, will be recorded as the AE.  AEs are reported  on 
the appropriate case report form ( CRF) when prompted.  
10.1.2  Criteria for Serious ness 
Events are s erious if they lead to one of the following outcomes :  
 Death  
 Life-threatening (i.e., an immediate threat to life)  
 Hospitalization or prolongation of hospitalization  
 Persistent or significant incapacity or substantial disruption of the abil ity to 
conduct normal life functions  
 Congenital abnormalities/birth defects  
 Other important medical evens that may jeopardize the participant and/or may 
require intervention to prevent one of the outcomes listed above   
10.1.3  Unanticipated  Problems  
An unanticipated problem (UP) is any incident, experience or outcome that is:  
1. Unexpected in terms of nature, severity, or frequency in relation to:  
a. the research risks that are described in the IRB -approved research protocol 
and informed consent document; Inve stigator’s Brochure  (IB) or other study 
documents; and  
b. the characteristics of the population being studied; and  
2. Possibly, probably, or definitely related to participation in the research; and  
3. Places study participants or others at a greater risk of harm (including physical, 
psychological, economic, or social harm) than was previously known or 
recognized.  
 
Furthermore, a UP could be an expected event that occurs at a greater frequency 
than would be expected based on current knowledge of the disease and tre atment 
under study.  The DSMB providing oversight to the study may make such an 
assessment based on an aggregate analysis of events.  
10.1.4  Severity  
The investigator will evaluate all AEs with respect to both seriousness  (results in 
outcomes as above)  and severity  (intensity or grade).  AEs will be graded for severity 
according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse 
Events , (also known as the DAIDS AE Grading Table; see Appendix D for the URL).  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
47 
 For specific events that are not included in the DAIDS AE Grading Table, the generic 
scale below  is to be used:  
TABLE 3. GENERIC AE GRADING SCALE  
Grade 1  Symptoms causing no or minimal interference with usual social and 
functional activities  
Grade 2  Symptoms causing greater than minimal interference with usual social 
and functional activities  
Grade 3  Symptoms causing inability to perform usual social and functional 
activities  
Grade 4  Symptoms causing inability to perform basic self -care functions, or 
medical or operative intervention indicated to prevent permanent 
impairment, persistent disability, or death  
Grade 5  Events resulting in death  
 
10.1.5  Causality  
Causality refers to the likelihood that the event is related to the study intervention.  It will 
be assessed for  SAEs and UPs.  This assessment will be made for both the agent under 
investigation (hIVIG) and the study -provided background therapy of remdesivir  using the 
following guidelines:  
 Reasonable possibility  – There is a clear temporal relationship between the study 
intervention and the event onset, and the AE is known to occur with the study 
intervention or there is a reasonable possibility that the study intervention caused the 
AE. Reasonable possibility me ans that there is evidence to suggest a causal 
relationship between the study intervention and the AE.  
 
 No reasonable possibility  – There is no evidence suggesting that the study 
intervention caused the event, there is no temporal relationship between the study 
intervention and event onset, or an alternate etiology has been established.  
 
The causality assessment  is based on available information at the time of the 
assessment of the event.  The investigator may revise these assessments as additional 
informat ion becomes available . 
10.1.6  Expectedness  
Expectedness will be assessed for SAEs using the Reference Safety Information section 
of the IBs for the hIVIG and remdesivir.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
48 
 The expectedness assessment is based on available information at the time of the 
assessment o f the event.  The investigator may revise these assessments as additional 
information becomes available.  
 Schedule for Data Collection and Reporting of Specific 10.2
Events  
10.2.1  Infusion -related reactions  
Infusion related signs/symptoms of any grade that  are new or h ave increased in 
grade compared to their pre -infusion level are reported for the hIVIG/p lacebo if they 
occur during or within  2 hours post infusion.  Any infusion related reaction assess ed 
as meeting SAE criteria will be reported as an SAE.  Similarly, any  grade 3 or 4 
infusion related reaction will be reported as an AE.  
 
10.2.2  Targeted Laboratory abnormalities  
Selected laboratory tests are performed prior to infusion and on Day 7. These values 
are associated with a severity grade centrally using the laboratory test results 
reported on the eCRFs with normal ranges, and with the DAIDS AE Grading Table . 
 
Other laboratory abnormalities identified in the course of the participant’s cli nical care 
are not reported as AEs (e.g., an isolated elevated glucose level) unless they are 
associated with a specific clinical diagnosis/syndrome, in which case they are 
reported if they meet the reporting criteria of one of the oth er safety outcomes.  In 
addition , if an isolated laboratory test result meets SAE reporting criteria  (e.g., a 
serious event related to the study intervention) , it should be reported as an SAE.  
 
10.2.3  Clinical adverse events of any grade severity on Days 0, 1, 3, 7 and 28  
On Day 0 prior to infusion and on Days 1, 3, 7 and 28 the prevalence of AEs of any 
grade severity that the participant reports that day will be collected.  This information 
supplements the information on grade 3 and 4 events through Day 7 that is collected.  
10.2.4  Incid ent Grade 3 and 4 clinical adverse events through Day 7  
From the time of randomization on Day 0 through Day 7, clinical events reaching 
Grade 3 or 4 severity level will be reported as AEs unless they are a protocol -
specified exempt event (see below).   
 
Any medical condition of grade 1 and 2 that is present at Day 0 will be reported as an 
AE if it increases to Grade 3 or 4 by Day 7. 
 
Isolated laboratory abnormalities will not be recorded on the eCRF  for grade 3 and 4 
events .  However, as noted above, if an isolated laboratory result meets SAE criteria, 
it should be reported as an SAE.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
49 
 10.2.5  Protocol -specified exempt events  
These events are listed in sections 4.1 and 4.2 and are collected systematically 
during study follow -up on eCRFs . These events will not be repo rted as Grade 3 or 4 
AEs even if they occur at that severity grade.  They also will not be reported as SAEs, 
even if they meet one or more of the criteria for seriousness, unless the investigator 
considered that there was a reasonable possibility that the study intervention 
caused the event .  These events may occur during the initial hospitalization, lead to 
a re-admission, or occur in a later hospitalization during follow -up.  
The following are protocol -specified exempt events : 
 Death  
 Stroke  
 Meningitis  
 Encephalitis  
 Myelitis  
 Myocardial infarction  
 Myocarditis  
 Pericarditis  
 New onset of worsening of CHF (NYHA class 3 or 4)  
 Arterial or deep venous  thromboembolic events  
 Respiratory failure  defined as receipt of high flow nasal oxygen, noninvasive  
ventilation, or invasive ventilation  
 Hypotension requiring vasopressor therapy  
 Renal dysfunction requiring renal replacement therapy  
 Hepatic decompensation  
 Acute  delirium  
 Disseminated intravascular coagulation  
 Microbiologically -proven severe infection (n ot including SARS -CoV-2) 
 
10.2.6  Reportable SAEs  
Reportable SAEs for this study are:  
 Serious clinical AEs not reported as a study endpoint; and  
 Any serious AE related to the study intervention  
Deaths, life -threatening events, and others SAEs considered related to the 
investigational agent, irrespective of whether the event is mentioned above as a 
protocol -specified exempt event, that occur from the time of infusion of the 
hIVIG/placebo  begins th rough the Day 28 visit must be reported by sites on the SAE 
eCRF to the sponsor via the INSIGHT Safety Office.   These events must be reported  
within 24 hours of site awareness.   All other SAEs must be reported within 3 days 
of site awareness.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
50 
 SAEs are fol lowed until the outcome of the SAE is known.  If the outcome of an SAE 
is still unknown at the time of the final follow -up visit (Day 28), the outcome will be 
entered in the database as “unknown.”  
Suspected unexpected serious adverse reactions (SUSARs) are  SAEs that are 
assessed as related to a study -provided treatment and are unexpected per the 
Reference Safety Information of the IB for that treatment.  SUSARs are reported from 
the INSIGHT Safety Office to applicable regulators in an expedited fashion.  SU SARs 
that result in death or are immediately life -threatening are reported to regulators 
within 7 calendar days of receipt.  All other SUSARs are reported to regulators within 
15 calendar days.  The INSIGHT Safety Office will generate a Safety Report for e ach 
SUSAR for distribution to investigators and other parties.  Investigators are 
responsible for submitting Safety Report summaries that are received from the 
sponsor to their overseeing IRB/EC.  Investigators must also comply with all reporting 
requireme nts of their overseeing IRB/EC.  
Safety reports for SUSARs indicate the study intervention (i.e., are unblinded).  
SAEs that are not protocol -specified exempt events and that are not related to the 
study intervention (investigational agent or treatment provi ded as SOC) must be 
reported on the SAE eCRF within 3 days of site awareness.  
 
10.2.7  Unanticipated Problems (U Ps) 
UPs must also be reported via the appropriate eCRF to the INSIGHT Safety Office no 
later than 7 calendar days after site awareness of the event. Inv estigators are 
responsible for submitting UPs that are received from the sponsor to their overseeing 
IRB/EC.  Investigators must also comply with all reporting requirements of their 
overseeing IRB/EC.  
 
10.2.8  Deaths  
Deaths that are considered unrelated to the study intervention are reported on the 
eCRF for deaths.   Deaths considered related to the study intervention (investigational 
agent or study -supplied SOC) must also be reported as an SAE.   
 Medical  Monitor  10.3
A Medical Monitor appointed by the sponsor will be responsible for reviewing all 
SAEs, making an independent assessment of causality and expectedness, preparing 
sponsor safety reports,  and communicat ing as needed with the DSMB and the 
Investigational New Drug ( IND) holder.  
 
 Treatment Interruption or Disc ontinuation  10.4
An infusion  may be interrupted or discontinued at any time at the participant ’s request 
or at the discretion of the Investigator or Sponsor. Reasons for interruption or 
discontinuation and the total volume administered will be recorded.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
51 
  Halting Rules  10.5
The sponsor medical monitor or the DSMB may request that enrol lment be halted for 
safety reasons (e.g., unacceptabl y high rate of infusion -related reactions or other 
unanticipated AEs).  As a guideline, the DSMB will be asked to consider halting 
enrollment if mo re than 5% of participants experience a grade 3 or 4 infusion AE or if 
more than 10% do not complete the infusion due to an AE(s). This will be informed by 
the lower bound of the confidence interval. If the study is temporarily halt ed or 
stopped for safety reasons, IRBs/ethics committees will be informed.  
The IND holder and s ponsor, in collaboration with the  protocol chair  and the DSMB 
will determine if it is safe to resume the study. The sponsor will notify the Site 
Investigators o f this decision. The conditions for resumption of the study will be 
defined in this notification. The Site Investigators will notify their local IRB s/ethics 
committees  of the decision to resume the study.  
 EVALUATION  11
 Data Analysis  11.1
A brief summary of the sta tistical considerations is provided here, full details will be 
described in a statistical analysis plan (SAP)  that will be finalized prior to unblinding 
of the data.  Data unblinding will either occur after a recommendation from the 
independent DSMB or after all participants complete the Day 28 follow -up visit.  
The primary analysis will be by intention to treat  comparing all pa rticipants  
randomized to hIVIG with those randomized to placebo.  The different  hIVIG products 
will be pooled for this analysis .  
This analysis plan applies to the primary efficacy and safety  outcomes,  and important 
secondary outcomes . 
For the primary endpoint, the percent of pa rticipants  in the 7 categories of the ordinal 
outcome will be compared.  A proportional odds model will be u sed to estimate a 
summary OR.82 The model will include a  single indicator for treatment , indicators for 
the pa rticipant ’s clinical state at entry (categories of ordinal outcome) , and its two -way 
interactions with the six cut -offs. The model will also includ e indicators for which of 
the four hIVIG  product /matching placebo  product was used  and their two -way 
interactions with the six cutoffs for each of the six cumulative odds of improvement . A 
test for the proportional odds assumption  will be carried out.  Even if the proportional 
odds assumption is violated, the overall summary OR will be the basis for inference 
based on the primary analysis. In order to further characterize the summary OR and 
any deviations from proportional odds , separate ORs will be est imated for each of the 
six dichotomized definitions of improvement that can be formulated from the 
components of the ordinal outcome.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
52 
 For the primary endpoint analysis only, multiple imputation based on baseline and 
follow -up data will be used to estimate  participant status at day 7 for participants with 
missing follow -up data.  For this imputation the following baseline covariates will be 
considered in addition to an indicator for treatment group: age, geographic region, 
clinical status based on the ordin al outcome at enrollment, presence of comorbidities, 
NEW score, and oxygen saturation. In addition to these baseline covariates, the last 
NEW score and the last value of the ordinal outcome measured will be used in the 
imputation.  
We will impute ten data s ets; parameter estimates (e.g., the summary odds ratio) 
from the 10 multiply imputed dataset s will be combined using Rubin’s combining 
rules. The imputation will take into account whether partial information concerning the 
ordinal outcome at Day 7 is known  (e.g., it is known that the patient is alive and no 
longer hospitalized and receiving supplemental oxygen and only which of the best 2 
categories the patient is in is unknown).  
Categories 3 and 4 of the primary ordinal outcome differ in part by the amount  of 
supplemental oxygen required, and a single cut point  (4 liters/minute) defines the 
difference. Since, together, these 2 categories of the ordinal outcome are expected to 
include approximately 30% of participants, an analysis that combines these two 
categories (a 6 -category ordinal outcome) will be carried to supplement the primary 
analysis  using the same methods described above.   
SAEs and grade 3 and 4 events (excluding isolated  laboratory abnormalities) will be 
classified by system organ class accordin g to MedDRA . The composite of incident  
grade 3 or 4 event s, an SAE or death over 7 days of follow -up will be summarized 
with Mantel Haen szel chi -square tests stratified by hIVIG/matched placebo group . 
Time to event methods  (e.g., Kaplan -Meier estimates and Cox regression)  will be 
used to summarize deaths and SAEs through Day 28 . 
Safety analyses will also include infusion reactions collected during or within 2 hours 
after the infusion of hIVIG/placebo.  Percentages of partic ipants who experience 
infusion reactions or prematurely terminated infusions will be summarized by 
treatment groups, and Cochran Mantel Haenszel tests will be used to compare 
groups.  
For secondary endpoints such as time to discharge  and time to the 2 most favorable 
categories of the primary ordinal outcome , time to event methods that take into 
account the competing risk of death  will be used . Specifically, Gray’s test with rho=0, 
the Fine -Gray model, and the Aalen -Johansen estimator for the cumulative incid ence 
curve are the competing risk equivalents to the log -rank test, Cox proportional 
hazards model , and the Kaplan -Meier estimator for the cumulative proportion of 
participants with the event, respectively.83,84,85 
Longitudinal random effects models will be used to summarize log -transformed 
antibody level differences between the hIVIG and placebo groups at Days 1, 3, 7 and 
28 of follow -up. Baseline antibody levels will be included as a cova riate in these 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
53 
 models.  For the subset of participants for whom blood is collected at Day 90, 
antibody levels  will be compared.   
Subgroup analyses for the primary 7-category ordinal outcome (primary efficacy 
outcome), as well as for the primary safety outcome  (Grade 3 and 4 event s, SAE or 
death through Day 7) will be performed to determine whether the treatment effect 
(hIVIG versus placebo) differs across baseline -defined subgroups. The key subgroup 
analys is is by duration of symptoms at study entry .  For the subgroup of participants 
in the lower 3 quartiles, the OR for the primary ordinal outcome at Day 7 is 
hypothesized to be greater than the overall result and those in the upper quartile  
(longest duration of symptoms at study entry) .  The difference in ORs will be 
compared for those  in the lower 3 quartiles versus the upper quartile.  In addition, the 
trend across the four quartiles will be asses sed.   
The following other baseline -defined subgroups will be considered:  age, gender, 
race/ethnicity, BMI, history of chronic conditions,  geographic region, hIVIG product  
administered , neutralizing antibody level , baseline u pper respiratory SARS -CoV-2 
viral load ,  oxygen saturation level, ordinal outcome category at entry, NEW S, 
dyspnea severity , and a disease progression score . A priori  we have no reason to 
believe the clinical efficacy or safety of hIVIG compared to placebo will be 
substantially different in any of the subgroups considered. These analyses will be 
approached cautiously because random differences can occur  (type 1 error is i nflated 
due to the number of subgroups examined),  confounding due to other factors in 
defining each subgroup is possible, and power is limited . To partially control the 
inflation of type 1 error and to guide the interpretation of subgroup summaries,  an 
overall test of heterogeneity of treatment effect (treatment by subgroup interaction) 
will be constructed to assess how strong the evidence is that the treatment effect 
varies across the baseline subgroups.  
In addition to these subgroup analyses, a subgroup analysis by lot potency will be 
carried out.  The aim of this analysis will be to determine if the primary outcome 
varies by range in potency among the various lots of hIVIG used.  The potency of 
each lot will be measured by a central laboratory.  Participants in the placebo group 
will be classified according the lot potency they would have received had they been 
randomly assigned to the hIVIG group.  The methods used for this subgroup analysis 
will be as de scribed above.  
If there is a beneficial effect of hIVIG  compared to placebo , in order to support 
regulatory claims for each hIVIG product used, sensitivity analyses comparing each 
hIVIG product to its matched placebo will be carried out for key efficacy a nd sa fety 
endpoints . These analyses will consider that each hIVIG product will be used by a 
different group of clinical sites  (i.e., each comparison will represent a small multi -
center trial), and that power w ill likely be very low for all of the outcomes.  These 
analyses are referred to as sensitivity analyses because overall therapeutic efficacy 
and safety will be based on the pooled analysis of the four hIVIG products with 
placebo.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
54 
 If the hIVIG and placebo groups differ for the primary ordinal outcome at Day 7, the 
extent to which a favourable treatment difference for hIVIG can be explained by 
antibody levels measured at baseline and Days 1, 3, 7, and 28  of follow -up will be 
investigated.  
 Ethical Conduct of the Study  11.2
The study will be conducted according to the Declaration of Helsinki in its current 
version; the requirements of Good Clinical Practice (GCP) as defined in Guidelines, 
EU Clinical Trials Directive (2001/20/EC), and EU GCP Directive (2005/28/EC); 
Internatio nal Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) Guidelines; Human Subject Protection and 
Data Protection Acts; the US Office for Human Research Protections (OHRP); or with 
the local law and regulation, whiche ver affords greater protection  of human subjects . 
  Data Monitoring by an Independent DSMB  11.3
An independent DSMB will review the study prior to initiation and at frequent  intervals 
during the trial. The DSMB will review safety data for first 20 to 30 participants 
randomized after they have been followed for 7 days.  Thereafter, the DSMB will 
review safety data at 30 day intervals. Safety summaries will include the safety 
outcomes in section 4.2. The DSMB may also convene additional reviews as 
necessary.  After each meeting they will recommend continuing the study as planned, 
modifying the study, or terminating the study .  
The DSMB will be asked to recommend early termination or modification only when 
there is clear and substantial evidence of a treatment difference.  As a guideline, 
asymmetric  boundaries will be provided to the DSMB to monitor the primary endpoint 
comparison.  For monitoring early benefit of hIVIG , the Lan -DeMets spending function 
analog ue of the O’Brien -Fleming boundar y will be used86,87; a H aybittle -Peto type 
boundary using a 2.5 standard deviation (SD) difference for the first 100 participants 
enrolled and 2.0 SD afterwards will used as a guideline for harm .88 The Lan-DeMets 
boundary used will be chosen to preserve a 1 -sided 0.025 level of significance.  For 
computing the Lan-DeMets boundar y, the information fraction at each interim 
analysis will be the number of participants who have completed 7 days of follow -up 
divided by the target sample size ( currently  500). With this guideline for early 
termination , less evidence will be required for crossing a boundary for ha rm than 
benefit.  
Futility analyses will also be presented to the DSMB for the primary endpoint 
comparison by the unblinded statisticians based on conditional power estimates.  
Conditional power incorporates the observed results by treatment group thus far (and 
uses the originally as sumed treatment effect for future data) to calculate the 
conditional probability of obtaining a significant result by the end of the trial.  If 
conditional power, given the observed data and assuming the originally hypothesized 
treatment effect thereafter, is less than 20% after 50% of information (primary 
endpoints) is available, consideration should be given to stopping the trial.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
55 
 A SAP will be developed to guide DSMB interim analyses.  The SAP will include 
recommended analyses for the DSMB to consider in a ddition to the primary endpoint 
analysis in the event early termination for efficacy or futility is considered.  For 
example, the primary endpoint at Day 7 for the key previously defined subgroup of 
those in the lower 3 quartiles of symptom duration  at entr y will be routinely 
summarized  in the closed interim report to the DSMB . 
All of t hese analyses will consider the timeliness of reporting primary outcome data, 
secondary efficacy and safety outcomes, and subgroups.   
 PROTECTION OF HUMAN SUBJECTS AND ETHICAL  12
CONSIDERATIONS   
 Participating Clinical Sites and Local Review of Protocol and 12.1
Informed Consent  
This study will be conducted by major medical centers participating in the 
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT).  It is 
anticipated that potential participants will be recruited by the site investigators and/or 
that positive SARS -CoV-2 laboratory testing will be used to enquire about potential 
enrollment.  Information about this study will be disseminated to health car e providers 
in these settings.  
Prior to the initiation of the study at each clinical research site, the protocol, informed 
consent form and any participant information materials will be submitted to and 
approved by a central/national IRB or EC  and/or the s ite’s local IRB/EC . Likewise, 
any future amendments to the study protocol will be submitted and approved by the 
same  IRB(s) or EC (s). After IRB/EC approval, sites must register for this study before 
screening potential participants and  must register for an y protocol amendments.  
Specific p rotocol registration information can be found  in the Study Procedure 
Modules . 
 Informed Consent of Study Participants   12.2
Informed consent must be obtained (see sample  in Appendix A ) prior to conducting 
any study -related procedures.   For patients who are incapacitated, informed consent 
may be obtained from a legally authorized representative.  Capacity will be assessed 
according to local standards and policies.  Local standards and policies wil l also 
determine who is legally authorized to consent for an individual who is incapacitated.  
Should the individual regain capacity during the study, their direct consent should be 
obtained at the earliest opportunity.   Electronic consent methods may be u sed if 
approved by the IRB/EC.  Procedures for recording of written consent may be 
modified for infection control purposes as approved by the IRB/EC.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
56 
  Confidentiality of Study Participants   12.3
The confidentiality of all study participant s will be protected in a ccordance with GCP  
Guidelines and national regulations.  
 Regulatory Oversight  12.4
Sites in the US will conduct this trial under the terms of the IND and will adhere to 
FDA regulations found in 21 CFR 312, Subpart D.  Sites in countries other than the 
US will no t conduct the trial under the IND.  All sites will conduct the trial in 
accordance with the requirements of GCP as codified in their local law and 
regulation, under the oversight of their institution and competent regulatory authority.  
A specific protocol m onitoring plan will be developed.  The plan will outline the 
frequency of monitoring visits based on such factors as study enrollment, data 
collection status, and regulatory obligations.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
57 
 APPENDIX A -1 SAMPLE INFORMED CONSE NT FORM  
(FOLLOW -UP ENDING DAY 28)  
Short Title: Inpatient Treatment with Anti -Coronavirus Immunoglobulin (ITAC)  
Sponsored by:  The University of Minnesota  
A Multicenter Study of the  
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)  
Full Title of the Study:  An International Multicenter, Adaptive, Randomized 
Double -Blind , Placebo -Controlled  Trial of the Safety , Tolerability  and Efficacy of 
Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of 
Adult  Hospitalized Patients  at Onset of Clinical Progression of COVID -19 
CONSENT FOR PARTICIPATING IN A  NATIONAL INSTITUTES OF HEALTH ( NIH)-
FUNDED RESEARCH STUDY  
SITE INVESTIGATOR: ________________________________ PHONE: __________  
  
 
 
 
 
 
 
 
 
 
 
 
  
OHRP Requirements to be read by the sites:  
PLEASE NOTE THAT THIS SAMPLE LANGUAGE DOES NOT PREEMPT OR REPLACE LOCAL 
IRB/EC REVIEW AND APPROVAL.  INVESTIGATORS ARE REQUIRED TO PROVIDE THE LOCAL 
IRB/EC WITH A COPY OF THIS SAMPLE LANGUAGE ALONG WITH THE LANGUAGE INTENDED 
FOR LOCAL USE.  LOCAL IRBs/ECs ARE REQUIRED TO WEIGH THE UNIQUE RISKS, 
CONSTRAINTS, AND POPULATION CONSIDERATIONS AS A CONDITION OF ANY APPROVAL.  
ANY DELETION OR SUBSTANTIVE CHANGE OF INFORMATION CONCERNING RISKS OR 
ALTERNATIVE TREATMENT MUST BE JUSTIFIED BY THE INVESTIGATOR, APPROVED BY THE 
LOCAL IRB/EC, AND NOTED IN THE IRB/EC MINUTES.  JUSTIFICATION AND IRB/EC APPROVAL 
OF SUCH CHANGES MUST BE FORWARDED TO THE INTERNATIONAL COORDINATING 
CENTER.   SPONSOR -APPROVED CHANGES IN THE PROTOCOL MUST BE APPROVED BY THE 
LOCAL IRB/EC BEFORE USE U NLESS INTENDED FOR THE ELIMINATION OF APPARENT 
IMMEDIATE HAZARD.  NEW INFORMATION SHALL BE SHARED WITH EXISTING SUBJECTS AT 
NEXT ENCOUNTER, WITH ALL NEW SUBJECTS PRIOR TO INVOLVEMENT, OR AS THE LOCAL 
IRB/EC MAY OTHERWISE ADDITIONALLY REQUIRE.  ALL SITE INSTRUCTION THAT IS INCLUDED IN A TEXT BOX SHOULD BE 
REMOVED FROM THE SITE’S INFORMED CONSENT FOR PARTICIPANTS  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
58 
 Key information:   
We are asking you to join a research study about COVID -19. It is your choice whether or not 
you want to join.  This form gives you information about the study that will help you make 
your choice.  You can discuss this information with your d octor or family or anyone else you 
would like before you make your choice.  Your choice will not affect the care you are getting 
for COVID -19. 
What is the research question?  
We are trying to find out if giving  anti-coronavirus hyperimmune  intravenous immunoglobulin 
(hIVIG) can help people in the hospital with COVID -19 have fewer bad effects from COVID -
19, get better faster, and get out of the hospital faster.  Anti-coronavirus hIVIG contains 
antibodies against the virus that causes COVID -19. We think this will help your body fight 
COVID -19 better, but we are not sure and so we are doing this study.  We are asking you to 
join the study because you are in the hospital with COVID -19.  
What do you have to do if you decide to be in the study?  
The study staff at your hospital will make sure it is safe for you to be in the study.  They will 
check your medical history.  They will look at routine medical test results that you are 
probably already having done regularly in the hospital.   
If you agree to be  in the study, we will randomize you to one of two study groups.  It will be 
up to chance, like flipping a coin, and you will have an equal chance (50/50) of getting either 
hIVIG or a saline placebo (a salt solution).  Your doctor will not decide which of th ese you will 
get, and neither you nor your doctor or study staff will know what treatment you are getting.   
You will get the usual supportive care for COVID -19 recommended by your hospital , just as 
you would if you do not join the s tudy. In addition, the s tudy will supply an antiviral drug 
called remdesivir, unless there is a medical reason that you should not get remdesivir. 
Remdesivir has been shown in other studies to improve recovery from COVID -19 in persons 
who have been hospitalized.  
You will get the study treatment ( hIVIG or placebo) once, on the day you join the study.  You 
will get it by a drip through a tube attached to a needle in your arm (intravenously).  It will 
take about 1-2 hours , though it may sometimes take longer depending on how your body 
reacts to the infusion . This is the only thing in the study that is experimental.  Everything else 
is part of routine medical care for someone in the hospital with COVID -19. 
You will get remdesivir once a day intravenously for up to 10 days while you are in  the 
hospital , as part of standard care for your COVID -19. 
You will also need to agree not  to participate in any other COVID -19 study for the first 7 
days you are in this study.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
59 
 You will be in the study for 28 days.  We will check on your health every day w hile you are in 
the hospital , and at regular intervals once you leave the hospital .  
We will collect the following information at these times:  
Up to 1 day 
before you 
get study 
treatment  Day 0 (the day 
you get study 
treatment)  Day 1 , Day 2,  
and 
Day 3  Day 5  
and Day 
14 Day 7  Day 28  
 Informed 
consent  
 Blood tests 
to check 
your health  
 Check to 
see how 
you are 
feeling  
 Pregnancy 
test 
 Your 
medical 
history   Infusion of 
study treatment  
 If you are taking 
certain 
medicines  
 Blood for future 
research ( 18 
mL, about 2 
tablespoon s) 
 Nasal swab  for 
future research   How you are 
feeling  
 Blood for 
future 
research ( 18 
mL, about 2 
tablespoon s)  How 
you are 
feeling   How you are 
feeling  
 If you are 
taking 
certain 
medicines  
 Blood tests 
to check 
your health  
 Blood for 
future 
research ( 18 
mL, about 2 
tablespoon s)  How you are 
feeling  
 Blood for 
future 
research ( 18 
mL, about 2 
tablespoon s) 
 
Day 28 is the last day you will be in the study.  
We may need to get some information from your medical record. By signing this consent, 
you also agree to let us get information for this study from your medical record.  
 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
60 
 We will send the information we collect to the University of Minnesota  (UMN)  in the US 
where it will be stored and analyzed.  In this information, only a code number, your year of 
birth, and a 3 -letter code that you or the study staff chooses will be used on your 
information . We never give information that could identify you, such as your name, address, 
birth date, or medical record number, to anyone outside this site.  The study staff at this site 
is responsible for keeping your identifying information safe from an yone who should not see 
it. We will send the blood samples to a laboratory in the US for storage.  We will keep them 
for as long as we have the funding and space to do so, which we hope will be many years.  
We will use the samples in the future for tests to help understand more about COVID -19 and 
how people respond to treatment for COVID -19. You and your doctor will not get any results 
from these tests.  We will not test your DNA (your genes).  We will not sell your samples and 
they will not be used for researc h aimed at making money (commercial research).  The 
samples will not have any information connected to them that could identify you.  
Why would you want to be in the study?  
If you get the hIVIG, it may help you get better faster, although we do not know that  for sure.  
Remember that half (50%) of the people in this study will not get the hIVIG.  
By being in this study, you help doctors know more about how to treat COVID -19 in people 
in the hospital.  Because so many people are getting hospitalized with COVID -19, this could 
be a big impact if a treatment proves to be effective.  
Why would you NOT want to be in the study?  
Only half (50%) of the people in this study will get the hIVIG.  You may not get the hIVIG.  If 
hIVIG turns out to be a good treatment, you would n ot get that benefit.  It’s also possible that 
if you do get hIVIG, it may turn out not to be useful, or may cause side effects that are 
harmful to you.  
What are the side effects of the study hIVIG treatment?  
hIVIG is usually very safe to give.  Similar immunoglobulin preparations have  been used in 
many different diseases over many year s, but immunogloblin prepared solely from 
individuals who have recovered from COVID -19 has not been studied before . In an earlier 
study of influenza h IVIG in peopl e in the hospital with the flu, over 150 people got hIVIG.  
There were no serious problems that occurred in people because they got hIVIG.  
All treatments cause side effects, and you may have some side effects from hIVIG.  About 
1% to  10% (1 in 100 people to  1 in 10 people) who get hIVIG get a fever, chills, nausea, 
vomiting, dizziness, shortness of breath, rash, hives, or headache, but these are usually not 
serious.   These can happen during the infusion or afterwards and usually go away on their 
own or with short -term treatment.   Although IVIG has been very safe for people with other 
diseases, less than 0.1%  (less than 1 in 1,000) of people taking other types of IVIG for other 
illnesses have had very serious reactions to it, including a kind of lung injury ca lled TRALI.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
61 
 People can have allergic reactions to drugs, including hives, trouble breathing, or other 
allergic responses. This is very rare but is also a possible effect of any drug. Allergic 
reactions may be severe or life -threatening.   
In some laborator y studies, infusions of antibodies have made  infections with viruses similar 
to the virus that causes COVID -19 worse. This is a very unlikely but possible side effect of 
the treatment infusion in this study, and you will be closely monitored for any signs of this 
effect.  
It is also possible that getting the study treatment infusions  could cause problems with your 
health because of the amount of fluid given to you for the study treatment if you have some 
other health condition that affects how your body hand les fluids.   You will get up to about  
400 mL of fluid for hIVIG or placebo, and about 100mL  each day for remdesivir if you 
receive it  
Some people may have some side effects after the hIVIG infusion s.  Other people may have 
no side effects.  You will be mon itored closely during the infusions, and short -term medical 
care will be provided if there are side effects from the infusions that can be treated.  
 
What are the benefits and risks or side effects of remdesivir treatment?  
Remdesivir was recently shown to help people who are in the hospital with COVID -19 to get 
better faster than people who got a placebo.  You may be given  remdesivir to treat your 
COVID -19 even if you do not join  this study. If your doctor considers that remdesivir is not a 
suitable treatment for you, you can still join this study, and you will receive hIVIG or placebo 
without remdesivir. For example, remdesivir might be unsuitable for you if you have serious 
liver or kidney problems or an allergy to it.  
 
The most commo n side effects of remdesivir include abnormal liver function test results, 
abnormal kidney function  test results, fever, elevated blood sugar, constipation, nausea, 
vomiting, decreased appetite, and headache. The abnormal liver  and kidney  function tests 
may last  a few days  or longer  but came back to normal levels over time . 
 
People can have allergic reactions to drugs, including hives, trouble breathing, or other 
allergic responses. This is very rare but is also a possible effect of any drug. Allergic 
react ions may be severe or life -threatening.   
 
Some people may have some side effects after the infusion  of remdesivir .  Other people 
may have no side effects.  You will be monitored closely during the infusions, and short -term 
medical care will be provided if  there are side effects from the infusions that can be treated.  
 
What are the side effects of the other study procedures?  
 
As shown in the table of what will happen at each visit, you will have some extra blood 
drawn for laboratory testing and storage.  Yo u will also have an extra swab of your nose and 
throat that would not be done if you are not in the study.  The risks and discomforts of these 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
62 
 extra blood draws and swab are no different than what you would  have  if they were 
performed as part of your regular hospital care for COVID -19. 
Additional information:  
Here is some additional information about the study that may help you make your choice 
about whether you want to be in the study.  
The US National Institutes of Health  (NIH) , an agency of the US Federal government, is 
paying for this study.  Because public money is paying for the study, we are required to 
comply with all rules and regulations about research.  We are doing this study according to 
internationally recognized standards of research as we ll as the laws of each country where 
the study is taking place.   
This study is taking place in several countries.  We expect to enroll about 500 people a round 
the world.  
You do not have to join this research study if you do not want to.  If you choose to joi n the 
study, you can stop at any time  by telling someone on the study team that you want to stop 
being in the study . If you choose not to join or to stop, your regular medical care will not 
change.  
If we get any new information that might change whether yo u want to join or stay in the 
study, we will tell you right away.   
Your study participation may be stopped without your consent if:  
 The groups overseeing the study decide the study should be stopped;  
 Your study team believes that being in the study is no l onger in your best interests.  
 
If your participation is stopped, you will still get the usual care given at your hospital for 
COVID -19. 
If you do not want to be in this study, you will still get the usual care to treat COVID -19. 
However, you cannot get the  hIVIG treatment, because it is experimental.  
 
What are the costs to you?  
We will give you the study treatment (hIVIG or placebo) at no cost.  We will also give you 
remdesivir at no cost.  We will pay for all clinic visits, lab work, and other tests that are part 
of this study . 
 
 
 THE NEXT PARAGRAPH IS FOR UNITED STATES SITES ONLY.  SITES IN 
OTHER COUNTRIES SHOULD DELETE THE NEXT PARAGRAPH.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
63 
  
You, your insurance company, or some other third -party payer must pay for all other 
medicines and hospital costs.  
 
 
 
Will you be paid to be in the study?  
We will compensate you for your time and inconvenience participating in the study.  [Specific 
details to be completed by site.]  
What if you are hurt as part of this study?  
If you are hurt because of being in this study , [insert the name of the hospital/clinic]  will treat 
your injury right away.  You or your insurance will have to pay for this treatment.  The study 
cannot pay you or pay for any care for study -related injuries or for your illness.  
 
 
 
What happen s to the blood samples  and respiratory swabs ? 
We will send the blood and respiratory swab samples to a central laboratory in the United 
States  of America . You and your doctor will not get the results of any tests done on these 
samples.  
The blood samples wi ll measure how many COVID -19 antibodies are in your blood.  This will 
tell us how your immune system responded to your COVID -19.  The nasal swab will 
measure how much virus you have in your respiratory system.  
Any blood samples that are left over after these tests will be stored at the central laboratory 
for as long as we are able to keep them.  We hope to use these in the future to answer other 
questions about COVID -19. You and your doctor will not get any results from these tests.  
Some of the blood will  also be given to the company that made the hIVIG to help them learn 
more about its effects.  
How do we protect your privacy?  
We will take every reasonable step to keep your health information private and to keep 
anyone from misusing it.  SITES OUTSIDE THE UNITED STATES:  Please replace the paragraph 
above with language appropriate for your location  
If the above is not true for your site, i.e., if trial insurance covers such 
cost, please replace the above with appropriate language.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
64 
 Your information (d ata) and samples will not be identified by name, or in any other way, in 
anything published about this study.   
We will do everything we can to keep your personal information private, but we cannot 
guarantee that nobody will get it.  We may have to release y our personal information if 
required by law.  
These people may see your medical and research information  at your site : 
 the [insert the name of the hospital/clinic]  ethics committee (institutional review board  
[IRB]); 
 the sponsor, other study research staff , and study monitors  
 US and other participating countries’ health regulatory agencies  
 the US National Institutes of Health which is funding the study  
They are committed to protecting your privacy.  
As the research staff at [inset the name of the hospital/clinic] , we are required to make sure 
that people not involved with this study cannot see your research and medical information.  
We will keep your research files in a safe place and will handle your personal information 
very carefully.  
Your study  data are sent electronically to the UMN in the US through a secure application.  
By signing this consent, you agree to hav e your data sent to UMN.  No information that could 
directly identify you is sent to UMN.  This is called “pseudonymized data.”  Access t o the data 
at UMN is limited through security measures, and no data breach or unauthorized access 
has ever occurred in this system.  After the study is over, the data will be stored securely for 
the period required by law.  
Your study data will be shared wit h the regulators that oversee the studies, as required by 
law. Your study data will also be shared with the drug company that provides the hIVIG to 
help them develop the drug.   
UMN may share your data and specimens with other people who study COVID -19. UMN  will 
remove any information that could possibly be used to identify you before sharing.  This is 
called “anonymizing the data.”  We will not ask you for additional consent for this sharing.  
UMN will only share data and specimens for research projects that a re approved by the 
group that is conducting this study.  
This study has a Certificate of Confidentiality from the US Federal government.  This means 
that UMN cannot share any data it has about you with national, state, or local civil, criminal, 
administrativ e, legislative, or other authorities unless you specifically allow us to share it.   
A description of this clinical trial will be available at http://www.ClinicalTrials.gov as required 
by U.S. law , and on the EudraCT website ( https://eudract.ema.europa.eu/ ). These website s 
will not include your name or any other direct identifiers such as your contact information.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
65 
 These websites  will include a summary of the results of this research  once the study has 
been completed . You can search either website at any time.  
[Note for US sites: The following brief HIPAA authorization is provided.  Your site -specific 
consent should be modified to reflect the HIPAA authorization language requirements at  
your site.]  
To do this research, we will collect and use your personal data, as described above and in 
any HIPAA Authorization Form we have given you.  Please tell us whether you agree to have 
us collect and use your personal data by placing your initials in front of your selection.
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
66 
 ____ Yes, I agree to the collection and processing of my personal data.  
 
____ No, I do not agree to th e collection and processing of my personal data.  
It is your choice whether you allow us to collect and use your data.  However, you will not be 
able to be in this research and have a chance to get the experimental treatment if we cannot 
collect and use your  data.  
[The following section (up to “What if you have problems or questions?”) is for countries 
subject to the General Data Protection Regulation ( GDPR ) or similar legislation requiring 
this information.  It should only be included in consents for sites su bject to such legislation.  It 
will vary from place to place whether it must be in this consent document, a separate 
consent document, or an information sheet that does not require signature.  The amount of 
information provided may be reduced to meet the requirements of a particular country (e.g., 
not all countries/ECs require an enumeration of all of a data subject’s rights).]  
What are your rights regarding your data?  
The UMN  is a public research university, and this study  is funded primarily by a grant f rom 
the US Federal government.  UMN  and the study  funding source require  the sponsor  (UMN)  
to follow regulations and policies that are meant to protect your privacy.  UMN is also 
required to comply with the General Data Protection Regulation ( GDPR ), because it 
processes data obtained from people in Europe .  
 
There is no  specific independent supervisory authority overseeing the processing of data in 
the US.  Any complaint you might have about the use of your data would be made to your 
national data protection a uthority.  
 
The GDPR gives you additional rights which we would like to inform you about below.  
 
Right to Information  
You have the right to know what data about you is being processed. You can also get a free 
copy of this data provided.  
 
Right to Correction  
You have the right to correct any information about you which is incorrect or had become 
incorrect.  
 
Right to Erasure/Anonymization  
The sponsor is required under both EU and US law to retain data from research studies like 
this one for many years.  However , you have the right to request that your personal data be 
completely anonymized. This is done by destroying the information at your study center that 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
67 
 links your identity to the pseudonymized data held by the sponsor.  This means that no one 
would ever be a ble to link the data held by the sponsor to you personally.  
 
Right to Restriction of processing  
Under certain conditions, you have the right to demand processing restrictions, i.e. the data 
may then only be stored, not processed. You must apply for this. Please contact your study 
physician or the data protection officer of the study center if you want to do so.  This right 
may be limited if the restriction would affect the reliability of the study results.  
 
Right to Data portability  
You have the right to receive the personal data that you have provided to the study center. 
This will allow you to request that this information be transmitted either to you or, where 
technically possible, to another agency designated by you.  
 
Right to Contradiction  
You have th e right to object at any time to any specific decision or action taken to process 
your personal data.  This right is limited for data that have already been processed and may 
be limited if your objection would affect the reliability of the study results.  
 
Right to Withdrawal of this consent  
You may withdraw your consent at any time with effect for future data collection. This 
withdrawal may be in an informal or verbal communication to your investigator.  If you 
withdraw your consent this will not affect the l awfulness of the data processing that has 
been or will be done with data collected until you withdraw consent.  Data already collected 
will be anonymized.  
 
If you would like to use one of these rights , please first contact the person responsible for 
the data collection at your study center:  
 
Person responsible for data collection  at the study center:  
Name:   
Address:   
Phone:   
Email   
 
For concerns about data processing and compliance with data protection requirements  you 
can also contact the data protection officer responsible for the study center:  
Data protection officer responsible  for the study center:  
Name:   
Address:   
Phone:   
Email   
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
68 
  
In addition, you have the right to lodge a complaint with the competent authority  if you 
believe that the processing of personal data concerning you is contrary to the GDPR:  
Data protection authority  responsible  for the study center:  
Name:   
Address:   
Phone:   
Email   
 
What if you have problems or questions?  
If you ever have  questions about this study, or about the storage or use of your data or 
samples, or if you are hurt by being in the study, contact:  
 [name of the investigator or other study staff]  
 [telephone number of the above]  
 
If you have questions about your rights as  a research participant, you can call:  
 [name or title of person on the ethics committee (IRB) or other organization 
appropriate for the site]  
 [telephone number of the above]  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
69 
 SIGNATURE PAGE FOR CONSENT TO PARTICIPATE IN THE INSIGHT 013 STUDY 
(Inpatient Tr eatment with Anti -Coronavirus Immunoglobulin , ITAC )  
I have read the consent or have had it explained to me. I am satisfied that I understand the 
information.  By signing this consent, I am stating that I want to join this study.  I understand 
that I do not waive any of my legal rights as a study participant by signing this consent.  I 
understand that I will receive a copy of the signed and dated consent.  
If you agree to be in this study, please sign below.  
 
________________________________________  Date: _______________  
Signature of participant  
 
________________________________________  
Printed name of participant  
 
_____________________________________   Date: _______________  
Signature of investigator/designee  
 
_____________________________________  
Printed name of investigator/designee  
 
FOR ADULTS NOT CAPABLE of GIVING CONSENT   
 
________________________________________   Date: _______________  
Signature of Legally Authorized Representative (LAR)  
 
_____________________________________  
Printed name of  LAR 
 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
70 
 ____________________________________  
Relationship of LAR to Participant  
(Indicate why the LAR is authorized to act as a surrogate health care decision -maker under state or applicable local law)  
 
Witness to Consent Interview  
 
On the date given next to my si gnature, I witnessed the consent interview for the research 
study named above in this document. I attest that the information in this consent form was 
explained to the subject, and the subject indicated that his/her questions and concerns were 
adequately a ddressed.  
_______________________________________  Date: _______________  
Signature of witness  
 
________________________________________  
Printed name of witness  
 
NOTE: This consent form, with the original signatures, MUST be retained on file by 
the Investigator of Record. A copy of the signed and dated consent must be given to 
the participant. A copy should be placed in the participant’s medical record, if 
applicab le.  
If no -touch / electronic consent is used, the participant must be provided with a copy 
of the consent in a manner appropriate to the method used to obtain it.  A record of 
the act of consent must also be appropriately retained in the participant’s med ical 
record.  
 
  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
71 
 APPENDIX A -2 SAMPLE INFORMED CONS ENT FORM 
FOR SITES COLLECTING  DAY 90 SAMPLES  
Short Title: Inpatient Treatment with Anti -Coronavirus Immunoglobulin (ITAC)  
Sponsored by: The University of Minnesota  
A Multicenter Study of the  
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)  
Full Title of the Study:  An International Multicenter, Adaptive, Randomized 
Double -Blind , Placebo -Controlled  Trial of the Safety , Tolerability  and Efficacy of 
Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of 
Adult  Hospitalized Patients  at Onset of Clinical Progression of COVID -19 
CONSENT FOR PARTICIPATING IN A NATIONAL INSTITUTES OF HEALTH (NIH) -
FUNDED RESEARCH STUDY  
SITE INVESTIGATOR: ________________________________ PHONE: __________  
  
 
 
 
 
 
 
 
 
 
 
 
  
OHRP Requirements to be read by the sites:  
PLEASE NOTE THAT THIS SAMPLE LANGUAGE DOES NOT PREEMPT OR REPLACE LOCAL 
IRB/EC REVIEW AND APPROVAL.  INVESTIGATORS ARE REQUIRED TO PROVIDE THE LOCAL 
IRB/EC WITH A COPY OF THIS SAMPLE LANGUAGE ALONG WITH THE LANGUAGE INTENDED 
FOR LOCAL USE.  LOCAL IRBs/ECs ARE REQUIRED TO WEIGH THE UNIQUE RISKS, 
CONSTRAINTS, AND POPULATION CONSIDERATIONS AS A CONDITION OF ANY APPROVAL.  
ANY DELETION OR SUBSTANTIVE CHANGE OF INFORMATION CONCERNING RISKS OR 
ALTERNATIVE TREATMENT MUST BE JUSTIFIED BY THE INVESTIGATOR, APPROVED BY THE 
LOCAL IRB/EC, AND NOTED IN THE IRB/EC MINUTES.  JUSTIFICATION AND IRB/EC APPROVAL 
OF SUCH CHANGES MUST BE FORWARDED TO THE INTERNATIONAL COORDINATING 
CENTER.   SPONSOR -APPROVED CHANGES IN THE PROTOCOL MUST BE APPROVED BY THE 
LOCAL IRB/EC BEFORE USE U NLESS INTENDED FOR THE ELIMINATION OF APPARENT 
IMMEDIATE HAZARD.  NEW INFORMATION SHALL BE SHARED WITH EXISTING SUBJECTS AT 
NEXT ENCOUNTER, WITH ALL NEW SUBJECTS PRIOR TO INVOLVEMENT, OR AS THE LOCAL 
IRB/EC MAY OTHERWISE ADDITIONALLY REQUIRE.  ALL SITE INST RUCTION THAT IS INCLUDED IN A TEXT BOX SHOULD BE 
REMOVED FROM THE SITE’S INFORMED CONSENT FOR PARTICIPANTS  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
72 
 Key information:   
We are asking you to join a research study about COVID -19. It is your choice whether or not 
you want to join.  This form gives you information about the study that will help you make 
your choice.  You can discuss this information with your d octor or family or anyone else you 
would like before you make your choice.  Your choice will not affect the care you are getting 
for COVID -19. 
What is the research question?  
We are trying to find out if giving  anti-coronavirus hyperimmune  intravenous immuno globulin 
(hIVIG) can help people in the hospital with COVID -19 have fewer bad effects from COVID -
19, get better faster, and get out of the hospital faster.  Anti-coronavirus h IVIG contains 
antibodies against the virus that causes COVID -19. We think this will help your body fight 
COVID -19 better, but we are not sure and so we are doing this study.  We are asking you to 
join the study because you are in the hospital with COVID -19.  
What do you have to do if you decide to be in the study?  
The study staff at your  hospital will make sure it is safe for you to be in the study.  They will 
check your medical history.  They will look at routine medical test results that you are 
probably already having done regularly in the hospital.   
If you agree to be in the study, we will randomize you to one of two study groups.  It will be 
up to chance, like flipping a coin, and you will have an equal chance (50/50) of getting either 
hIVIG or a saline placebo (a salt solution).  Your doctor will not decide which of these you will 
get, and neither you nor your doctor or study staff will know what treatment you are getting.   
You will get the usual supportive care for COVID -19 recommended by your hospital , just as 
you would if you do not join the s tudy. In addition, the study will supply a n antiviral drug 
called remdesivir, unless there is a medical reason that you should not get remdesivir. 
Remdesivir has been shown in other studies to improve recovery from COVID -19 in persons 
who have been hospitalized.  
You will get the study treatment ( hIVIG or placebo) once, on the day you join the study.  You 
will get it by a drip through a tube attached to a needle in your arm (intravenously).  It will 
take about 1-2 hours, though it may sometimes take longer depending on how your body 
reacts to the infu sion. This is the only thing in the study that is experimental.  Everything else 
is part of routine medical care for someone in the hospital with COVID -19. 
You will get remdesivir once a day intravenously for up to 10 days while you are in the 
hospital, as part of standard care for your COVID -19. 
You will also need to agree not to participate in any other COVID -19 study for the first 7 
days you are in this study.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
73 
  
You will be in the study for 90 days . We will check on your health every day while you are in 
the hospital , and at regular intervals once you leave the hospital .  
We will collect the following information at these times:  
Up to 1 day 
before you 
get study 
treatment  Day 0 (the day 
you get study 
treatmen t) Day 1, Day 2,  
Day 3, Day 28  Day 5 and 
Day 14  Day 7  Day 90  
 Informed 
consent  
 Blood 
tests to 
check your 
health  
 Check to 
see how 
you are 
feeling  
 Pregnancy 
test 
 Your 
medical 
history   Infusion of 
study 
treatment  
 If you are 
taking certain 
medicines  
 Blood for 
future 
research (18 
mL, about 2 
tablespoons)  
 Nasal swab 
for future 
research   How you are 
feeling  
 Blood for 
future 
research (18 
mL, about 2 
tablespoons)   How 
you are 
feeling   How you are 
feeling  
 If you are 
taking 
certain 
medicines  
 Blood tests 
to check 
your health  
 Blood for 
future 
research (18 
mL, about 2 
tablespoons)   Blood for 
future 
research (18 
mL, about 2 
tablespoons)  
 
We may need to get some information from your medical record. By signing this consent, 
you also agree to let us get information for this study from your medical record.  
 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
74 
 We will send the information we collect to the University of Minnesota  (UMN)  in the US 
where it will be stored and analyzed.  In this information, only a code number, your year of 
birth, and a 3 -letter code that you or the study staff chooses will be used on your 
information . We never give information that could identify you, such as your name, address, 
birth date, or medical rec ord number, to anyone outside this site.  The study staff at this site 
is responsible for keeping your identifying information safe from anyone who should not see 
it. We will send the blood samples to a laboratory in the US for storage.  We will keep them 
for as long as we have the funding and space to do so, which we hope will be many years.  
We will use the samples in the future for tests to help understand more about COVID -19 and 
how people respond to treatment for COVID -19. You and your doctor will not get  any results 
from these tests.  We will not test your DNA (your genes).  We will not sell your samples and 
they will not be used for research aimed at making money (commercial research).  The 
samples will not have any information connected to them that could identify you.  
Why would you want to be in the study?  
If you get the hIVIG, it may help you get better faster, although we do not know that for sure.  
Remember that half (50%) of the people in this study will not get the hIVIG.  
By being in this study, you he lp doctors know more about how to treat COVID -19 in people 
in the hospital.  Because so many people are getting hospitalized with COVID -19, this could 
be a big impact if a treatment proves to be effective.  
Why would you NOT want to be in the study?  
Only hal f (50%) of the people in this study will get the hIVIG.  You may not get the hIVIG.  If 
hIVIG turns out to be a good treatment, you would not get that benefit.  It’s also possible that 
if you do get hIVIG, it may turn out not to be useful, or may cause side  effects that are 
harmful to you.  
What are the side effects of the study hIVIG treatment?  
hIVIG is usually very safe to give.  Similar immunoglobulin preparations have  been used in 
many different diseases over many year s, but immunogloblin prepared solely f rom 
individuals who have recovered from COVID -19 has not been studied before . In an earlier 
study of influenza h IVIG in people in the hospital with the flu, over 150 people got hIVIG.  
There were no serious problems that occurred in people because they got hIVIG.  
All treatments cause side effects, and you may have some side effects from hIVIG.  About 
1% to  10% (1 in 100 people to 1 in 10 people) who get hIVIG get a fever, chills, nausea, 
vomiting, dizziness, shortness of breath, rash, hives, or headache, but  these are usually not 
serious.   These can happen during the infusion or afterwards and usually go away on their 
own or with short -term treatment.   Although IVIG has been very safe for people with other 
diseases, less than 0.1%  (less than 1 in 1,000) of pe ople taking other types of IVIG for other 
illnesses have had very serious reactions to it, including a kind of lung injury called TRALI.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
75 
 People can have allergic reactions to drugs, including hives, trouble breathing, or other 
allergic responses. This is v ery rare but is also a possible effect of any drug. Allergic 
reactions may be severe or life -threatening.   
In some laboratory studies, infusions of antibodies have made infections with viruses similar 
to the virus that causes COVID -19 worse. This is a ver y unlikely but possible side effect of 
the treatment infusion in this study, and you will be closely monitored for any signs of this 
effect.  
It is also possible that getting the study treatment infusions  could cause problems with your 
health because of the  amount of fluid given to you for the study treatment if you have some 
other health condition that affects how your body handles fluids.   You will get up to about  
400 mL of fluid for hIVIG or placebo, and about 100mL each day for remdesivir if you 
receive it 
Some people may have some side effects after the hIVIG infusion s.  Other people may have 
no side effects.  You will be monitored closely during the infusions, and short -term medical 
care will be provided if there are side effects from the infusions that  can be treated.  
 
What are the benefits and risks or side effects of remdesivir treatment?  
Remdesivir was recently shown to help people who are in the hospital with COVID -19 to get 
better faster than people who got a placebo.  You may be given  remdesivir t o treat your 
COVID -19 even if you do not join  this study. If your doctor considers that remdesivir is not a 
suitable treatment for you, you can still join this study, and you will receive hIVIG or placebo 
without remdesivir. For example, remdesivir might b e unsuitable for you if you have serious 
liver or kidney problems or an allergy to it.  
 
The most common side effects of remdesivir include abnormal liver function test results, 
abnormal kidney function  test results, fever, elevated blood sugar, constipatio n, nausea, 
vomiting, decreased appetite, and headache. The abnormal liver  and kidney  function tests 
may last  a few days  or longer  but came back to normal levels over time . 
 
People can have allergic reactions to drugs, including hives, trouble breathing, or  other 
allergic responses. This is very rare but is also a possible effect of any drug. Allergic 
reactions may be severe or life -threatening.   
 
Some people may have some side effects after the infusion  of remdesivir .  Other people 
may have no side effects .  You will be monitored closely during the infusions, and short -term 
medical care will be provided if there are side effects from the infusions that can be treated.  
 
What are the side effects of the other study procedures?  
 
As shown in the table of what will happen at each visit, you will have some extra blood 
drawn for laboratory testing and storage.  You will also have an extra swab of your nose and 
throat that would not be done if you are not in the study.  The risks and d iscomforts of these 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
76 
 extra blood draws and swab are no different than what you would  have  if they were 
performed as part of your regular hospital care for COVID -19. 
Additional information:  
Here is some additional information about the study that may help yo u make your choice 
about whether you want to be in the study.  
The US National Institutes of Health  (NIH) , an agency of the US Federal government, is 
paying for this study.  Because public money is paying for the study, we are required to 
comply with all rul es and regulations about research.  We are doing this study according to 
internationally recognized standards of research as well as the laws of each country where 
the study is taking place.   
This study is taking place in several countries.  We expect to enr oll about 500 people a round 
the world.  
You do not have to join this research study if you do not want to.  If you choose to join the 
study, you can stop at any time  by telling someone on the study team that you want to stop 
being in the study . If you choose  not to join or to stop, your regular medical care will not 
change.  
If we get any new information that might change whether you want to join or stay in the 
study, we will tell you right away.   
Your study participation may be stopped without your consent if : 
 The groups overseeing the study decide the study should be stopped;  
 Your study team believes that being in the study is no longer in your best interests.  
 
If your participation is stopped, you will still get the usual care given at your hospital for 
COVID -19. 
If you do not want to be in this study, you will still get the usual care to treat COVID -19. 
However, you cannot get the hIVIG treatment, because it is experimental.  
 
What are the costs to you?  
We will give you the study treatment (hIVIG  or placebo) at no cost.  We will also give you 
remdesivir at no cost.  We will pay for all clinic visits, lab work, and other tests that are part 
of this study.  
 
 
 THE NEXT PARAGRAPH IS FOR UNITED STATES SITES ONLY.  SITES IN 
OTHER COUNTRIES SHOULD DELETE  THE NEXT PARAGRAPH.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
77 
  
You, your insurance company, or some other third -party payer must pay for all other 
medicines and hospital costs.  
 
 
 
Will you be paid to be in the study?  
We will compensate you for your time and inconvenience participating in the study.  [Specific 
details to be completed by site.]  
What if you are hurt as part of this study?  
If you are hurt because of being in this study , [insert the name of the hospital/clinic]  will treat 
your injury right away.  You or your insurance will have to pay for this treatment.  The study 
cannot pay you or pay for any care for study -related injuries or for your illness.  
 
 
 
What happens to the blood samples  and respiratory swabs ? 
We will send the blood and respiratory swab samples to a central laboratory in the United 
States  of America . You and your doctor will not get the results of any tests done on these 
samples.  
The blood samples will measure how many COVID -19 antibodies are in your blood.  This will 
tell us how your immune system responded to your COVID -19.  The nasal swab will 
measure how much virus you have in your respiratory system.  
Any blood samples that are left over after these tests will be stored at the central laboratory 
for as long as we are able to keep them.  We hope to use these in the future to a nswer other 
questions about COVID -19. You and your doctor will not get any results from these tests.  
Some of the blood will also be given to the company that made the hIVIG to help them learn 
more about its effects.  
How do we protect your privacy?  
We will take every reasonable step to keep your health information private and to keep 
anyone from misusing it.  SITES OUTSIDE THE UNITED STATES:  Please replace the paragraph 
above with language appropriate for your location  
If the above is not true  for your site, i.e., if trial insurance covers such 
cost, please replace the above with appropriate language.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
78 
 Your information (data) and samples will not be identified by name, or in any other way, in 
anything published about this study.   
We will do everything we can to keep your personal information private, but we cannot 
guarantee that nobody will get it.  We may have to release your personal information if 
required by law.  
These people may see your medical and research information  at your site : 
 the [insert the  name of the hospital/clinic]  ethics committee (institutional review board  
[IRB]); 
 the sponsor, other study research staff , and study monitors  
 US and other participating countries’ health regulatory agencies  
 the US National Institutes of Health which is fu nding the study  
They are committed to protecting your privacy.  
As the research staff at [inset the name of the hospital/clinic] , we are required to make sure 
that people not involved with this study cannot see your research and medical information.  
We will keep your research files in a safe place and will handle your personal information 
very carefully.  
Your study data are sent electronically to the UMN in the US through a secure application.  
By signing this consent, you agree to hav e your data sent  to UMN.  No information that could 
directly identify you is sent to UMN.  This is called “pseudonymized data.”  Access to the data 
at UMN is limited through security measures, and no data breach or unauthorized access 
has ever occurred in this system.  After the study is over, the data will be stored securely for 
the period required by law.  
Your study data will be shared with the regulators that oversee the studies, as required by 
law. Your study data will also be shared with the drug company that provides the  hIVIG to 
help them develop the drug.  
UMN may share your data and specimens with other people who study COVID -19. UMN will 
remove any information that could possibly be used to identify you before sharing.  This is 
called “anonymizing the data.”  We will no t ask you for additional consent for this sharing.  
UMN will only share data and specimens for research projects that are approved by the 
group that is conducting this study.  
This study has a Certificate of Confidentiality from the US Federal government.  This means 
that UMN cannot share any data it has about you with national, state, or local civil, criminal, 
administrative, legislative, or other authorities unless you specifically allow us to share it.   
A description of this clinical trial will be available  at http://www.ClinicalTrials.gov as required 
by U.S. law , and on the EudraCT website ( https://eudract.ema.europa.eu/ ). These website s 
will not include your name or any other direct identifiers s uch as your contact information.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
79 
 These websites will include a summary of the results of this research  once the study has 
been completed . You can search either website at any time.  
[Note for US sites: The following brief HIPAA authorization is provided.  Your site -specific 
consent should be modified to reflect the HIPAA authorization language requirements at 
your site.]  
To do this research, we will collect and use your personal data, as described above and in 
any HIPAA Authorization Form we hav e given you.  Please tell us whether you agree to have 
us collect and use your personal data by placing your initials in front of your selection.
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
80 
 ____ Yes, I agree to the collection and processing of my personal data.  
 
____ No, I do not agree to the collectio n and processing of my personal data.  
It is your choice whether you allow us to collect and use your data.  However, you will 
not be able to be in this research and have a chance to get the experimental treatment if 
we cannot collect and use your data.  
[The following section (up to “What if you have problems or questions?”) is for countries 
subject to the General Data Protection Regulation ( GDPR ) or similar legislation 
requiring this information.  It should only be included in consents for sites subject to su ch 
legislation.  It will vary from place to place whether it must be in this consent document, 
a separate consent document, or an information sheet that does not require signature.  
The amount of information provided may be reduced to meet the requirements o f a 
particular country (e.g., not all countries/ECs require an enumeration of all of a data 
subject’s rights).]  
What are your rights regarding your data?  
The UMN  is a public research university, and this study  is funded primarily by a grant 
from the US Federal government.  UMN  and the study  funding source require  the 
sponsor  (UMN)  to follow regulations and policies that are meant to protect your privacy.  
UMN is also required to comply with the General Data Prote ction Regulation ( GDPR ), 
because it processes data obtained from people in Europe .  
 
There is no  specific independent supervisory authority overseeing the processing of 
data in the US.  Any complaint you might have about the use of your data would be 
made t o your national data protection authority.  
 
The GDPR gives you additional rights which we would like to inform you about below.  
 
Right to Information  
You have the right to know what data about you is being processed. You can also get a 
free copy of this data provided.  
 
Right to Correction  
You have the right to correct any information about you which is incorrect or had 
become incorrect.  
 
Right to Erasure/Anonymization  
The sponsor is required under both EU and US law to retain data from research studies 
like this one for many years.  However, you have the right to request that your personal 
data be completely anonymized. This is done by destroying the information at your 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
81 
 study center that links your identity to the pseudonymized data held by the sponsor.  
This means that no one would ever be able to link the data held by the sponsor to you 
personally.  
 
Right to Restriction of processing  
Under certain conditions, you have the right to demand processing restrictions, i.e. the 
data may then only be stored, not p rocessed. You must apply for this. Please contact 
your study physician or the data protection officer of the study center if you want to do 
so. This right may be limited if the restriction would affect the reliability of the study 
results.  
 
Right to Data p ortability  
You have the right to receive the personal data that you have provided to the study 
center. This will allow you to request that this information be transmitted either to you or, 
where technically possible, to another agency designated by you.  
 
Right to Contradiction  
You have the right to object at any time to any specific decision or action taken to 
process your personal data.  This right is limited for data that have already been 
processed and may be limited if your objection would affect the re liability of the study 
results.  
 
Right to Withdrawal of this consent  
You may withdraw your consent at any time with effect for future data collection. This 
withdrawal may be in an informal or verbal communication to your investigator.  If you 
withdraw your consent this will not affect the lawfulness of the data processing that has 
been or will be done with data collected until you withdraw consent.  Data already 
collected will be anonymized.  
 
If you would like to use one of these rights , please first contact the person responsible 
for the data collection at your study center:  
 
Person responsible for data collection  at the study center:  
Name:   
Address:   
Phone:   
Email   
 
For concerns about data processing and compliance with data protection requirements  
you can also contact the data protection officer responsible for the study center:  
Data protection officer responsible  for the study center:  
Name:   
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
82 
 Address:   
Phone:   
Email   
 
In addition, you have the right to lodge a complaint with the competent authority  if you 
believe that the processing of personal data concerning you is contrary to the GDPR:  
Data protection authority  responsible  for the study center:  
Name:   
Address:   
Phone:   
Email   
 
What if you have problems or questions?  
If you ever have  questions about this study, or about the storage or use of your data or 
samples, or if you are hurt by being in the study, contact:  
 [name of the investigator or other study staff]  
 [telephone number of the above]  
 
If you have questions about your rights as  a research participant, you can call:  
 [name or title of person on the ethics committee (IRB) or other organization 
appropriate for the site]  
 [telephone number of the above]  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
83 
 SIGNATURE PAGE FOR CONSENT TO PARTICIPATE IN THE INSIGHT 013 STUDY 
(Inpatient Tr eatment with Anti -Coronavirus Immunoglobulin , ITAC)   
I have read the consent or have had it explained to me. I am satisfied that I understand 
the information. By signing this consent, I am stating that I want to join this study. I 
understand that I do not waive any of my legal rights as a study participant by signing 
this consent. I understand that I will receive a copy of the signed and dated consent.  
If you agree to be in this study, please sign below.  
 
________________________________________  Date: ____ ___________  
Signature of participant  
 
________________________________________  
Printed name of participant  
 
_____________________________________   Date: _______________  
Signature of investigator/designee  
 
_____________________________________  
Printed name  of investigator/designee  
 
FOR ADULTS NOT CAPABLE of GIVING CONSENT   
 
________________________________________   Date: _______________  
Signature of Legally Authorized Representative (LAR)  
 
_____________________________________  
Printed name of  LAR 
 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
84 
 ____________________________________  
Relationship of LAR to Participant  
(Indicate why the LAR is authorized to act as a surrogate health care decision -maker under state or applicable local 
law) 
 
Witness to Consent Interview  
 
On the date given next to my signature, I witnessed the consent interview for the 
research study named above in this document. I attest that the information in this 
consent form was explained to the subject, and the subject indicated that his/her 
questions and concerns were adequately  addressed.  
_______________________________________  Date: _______________  
Signature of witness  
 
________________________________________  
Printed name of witness  
 
NOTE: This consent form, with the original signatures, MUST be retained on file 
by the Investigator of Record. A copy of the signed and dated consent must be 
given to the participant. A copy should be placed in the participant’s medical 
record, if applicab le.  
If no -touch / electronic consent is used, the participant must be provided with a 
copy of the consent in a manner appropriate to the method used to obtain it.  A 
record of the act of consent must also be appropriately retained in the 
participant’s med ical record.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
85 
 APPENDIX B  SCHEDULE OF ASSESSMEN TS 
 Screen  
or Day 0  Day 0  Follow -up Study Day 
 Shaded columns denote in -person visits  
Day −1/01 01 1 2 3 4 5 6 7 14 28 
Acceptable deviation from day  0 0 0 0 0 0 0 0 0 +3 +4 
ELIGIBILITY  & BASELINE DATA             
Informed consent  X           
Height and weight  X           
Baseline medical history (including 
day of illness from symptom onset)  X           
Baseline medications  X           
Symptom -directed  
physical exam  X           
Review SARS -CoV-2 test results  X           
Mid-turbinate  swab for central 
SARS -CoV-2 viral load testing  X           
Urine pregnancy test or other 
documentation of pregnancy status  X           
STUDY INTERVENTION             
Randomization   X          
Study Drug/Placebo Administration   X          
Assess infusion completion  and 
AEs  X          
STUDY PROCEDURES             
Clinical assessment for ordinal 
outcomes2  X X X X X X X X X X 
Vital signs for NEW score 
assessment3 X    X       
Hospitalization status      X  X  X X X 
Interim medical history          X X X 
Interim medication s         X   
Borg dyspnea scale  X        X   
Clinical a dverse events of any 
grade (present on day of 
assessment)   X X  X    X  X 
Incident g rade 3 and 4 adverse 
event s (all through Day 7)   X X X X  X  X   
Local laboratory  testing  X        X   
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
86 
 Resear ch sample storage (plasma  
and serum ) and central testing for 
immunoglobulin levels and 
neutralizing antibody titers4 X  X X X    X  X 
SAEs  and unanticipated problems  Report as they occur  
Deaths  Report as they occur  
Hospitalization Summary  Report upon hospital discharge  
1 Screening and randomization can be done in same session.  
2 Collected every day for inpatients and at Days 7, 14 and 28 for outpatients. 
3 Collected while hospitalized only  
4Consenting p articipants at  selected sites will also be seen at Day 90 (+10 days) to obtain a blood sample 
for central testing and storage  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
87 
  
APPENDIX C  INSIGHT 01 3 PROTOCOL TEAM  
To oversee the implementation of this treatment  study, membership on the protocol 
team will include:  
 Protocol co -chair(s)  
 NIAID, Division of Clinical Research representative s 
 INSIGHT University of Minnesota representatives  
 INSIGHT International Coordinating Center representatives  
 Collaborating laboratory representatives  
 Collaborating hIVIG manufacturers  
 Site investigators  
 Study biostatisticians  
 Community representative  
 
A core team consisting of the co -chair(s), ICC leaders, NIAID representatives, study 
statisticians and other representatives and the INSIGHT Principal Investigator ( PI) will also 
regularly convene to review study progress and address study conduct and administ rative 
issues that arise.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
88 
 APPENDIX D  REFERENCES ON THE IN SIGHT WEBSITE  
 
The INSIGHT website ( www.insight -trials.org ) will maintain updated links to the 
following documents referenced in the INSIGHT 01 3 protocol and to other information 
pertinent to the study:  
 
 DAIDS toxicity table: ( https://rsc.niaid.nih.gov/clinica l-research -sites/daids -adverse -
event -grading -tables ) 
 
 INSIGHT Publications and Presentations Policy  
((http://insight.ccbr.umn.edu/resources/P&P_policy.pdf ) 
 
 CDC and ECDC guidance on how to handle infection control measures  
(https://www.cdc.gov/sars/guidance/i -infection/healthcare.html ) and 
https://www.ecdc.europa.eu/en/publications -data/infection -prevention -and-control -
and-preparedness -covid -19-healthcare -settings )). 
 
 Treatment guidelines from NIH and WHO 
(https://www.covid19treatmentguidelines.nih.gov/ , 
https://www. who.int/emergencies/diseases/novel -coronavirus -2019/technical -
guidance/patient -management , https://www.idsociety.org/practice -guideline/covid -
19-guide line-treatment -and-management/ , and https://www.ersnet.org/covid -19-
guidelines -and-recommendations -directory )  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
89 
 APPENDIX E  LIST OF ACRONYMS  
µL microliter  
ADE Antibody -dependent enhancement  
AE adverse event  
ACTT  Adaptive COVID -19 Treatment Trial   
ALT alanine aminotransferase  
ARDS  acute respiratory distress syndrome  
AST aspartate aminotransferase  
B19V  parvovirus B19  
BMI body mass index  
CCP  convalescent plasma containing COVID -19 antibodies   
CDC  Centers for Disease Control and Prevention ( US) 
CI confidence inter val 
CMV  cytomegalovirus  
COVID -19 corona virus disease 2019  
CVA cerebrovascular accident  
DNA  deoxyribonucleic acid  
DSMB  Data and Safety Monitoring Board  
DVT deep vein thrombosis  
EC ethics committee  
ECMO  extra -corporeal membrane oxygenation   
eGFR  estimated glomerular filtration rate  
EU European Union  
FDA US Food and Drug Administration  
g gram(s)   
GCP  Good Clinical Practice  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
90 
 GDPR  General Data Protection Regulation  
HAV hepatitis A virus  
HBV hepatitis B virus  
HCV  hepatitis C virus  
HIV human immunodeficiency vir us 
hIVIG  hyperimmune intravenous immunoglobulin  
HR hazard ratio  
IB investigator’s brochure  
ICC International Coordinating Center  
ICH  The International Council for Harmonization of Technical 
Requirements for Pharmaceuticals for Human Use  
ICU  intensive care unit  
IEC Institutional Ethics Committee  
IgA, IgE, IgG, IgM  immunoglobulin A, E, G, M  
IL-6 interleukin 6  
INSIGHT  International Network for Strategic Initiatives in Global HIV Trials  
IQR interquartile range  
IRB Institutional Review Board  
IVIG intravenous immunoglobulin  
kg kilogram  
mg milligram  
MI myocardial infarction  
mL milliliter  
mmol millim ole(s)  
NEWS  National Early Warning Score  
NIAID  National Institute of Allergy and Infectious Diseases, NIH ( US) 
NIH National Institutes of Health ( US) 
nm nanometer(s)  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
91 
 OHRP  Office for Human Research Protections ( US) 
OR odds ratio  
PCR  polymerase chain reaction  
PHI personal health information  
RNA  ribonucleic acid  
SAE serious adverse event  
SAP statistical analysis plan  
SARS  severe acute respiratory syndrome  
SARS -CoV-2 severe acute respiratory syndrome coronavirus 2  
SD standard deviation  
SOC  standard of care  
SUSAR  suspected unexpected serious adverse reaction  
TACO  transfusion -associated circulatory overload  
TRALI  transfusion -related acute lung injury  
UMN  University of Minnesota  
UP unanticipated problem  
US United States of America  
WHO  World Health Organization  
WNV  West Nile virus  
  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
92 
 APPENDIX F  CLINICAL CATEGORICAL  DEFINITIONS FOR 
ORDINAL OUTCOME  
Each participant is categorized in the highest applicable category.  
Ordinal 
Category  Categorical 
Description  Categorical Definition * 
7 Death  Death  
6 End-organ failure  Currently r equiring invasive assisted ventilation, extracorporeal 
membrane oxygenation, mechanical circulatory support, 
vasopressor therapy or renal replacement therapy  
5 Life-threatening end -
organ dysfunction  Currently r equiring non -invasive assisted ventilation or high -
flow oxygen or 
Extra -pulmonary:  
Symptoms and signs of an acute stroke (NIHSS >  14)   
4 Serious end -organ 
dysfunction  Currently r equiring supplemental oxygen (≥ 4 liters/min, or ≥ 4 
liters/min above premorbid requirements **) but not high -flow 
oxygen  or 
Any of symptoms or signs of the following e xtra-pulmonary  
conditions : 
Stroke (NIH Stroke Scale/Score [NIHSS] ≤ 14), meningitis, 
encephalitis, or myelitis, myocardial infa rction, myocarditis, 
pericarditis, or New York Heart Association Class III or IV 
congestive heart failure, arterial or deep venous thrombosis  
including pulmonary embolism .  
3 Moderate end -organ 
dysfunction  Requiring supplemental oxygen < 4 liters/min, or < 4 liters/min 
above premorbid requirements ** 
2 Limiting symptoms due 
to COVID -19 Symptomatic and currently unable to independently undertake 
usual activities  
1 No limiting symptoms 
due to COVID -19 Can independently undertake usual activities with minimal or no 
symptoms  
*Continued hospitalization or presence in a particular category of inpatient facility ( e.g. intensive care or 
high dependency) is not used to divide these categories, as indication for continued hospitalization 
among recovering COVID patients is intrinsically subjective, in part determined by social and financial 
factors, and varies markedly acr oss the globe.  
** Premorbid requirement refers to requirements prior to the development of COVID -19, for example in 
patients with chronic obstructive pulmonary disease, other chronic pulmonary diseases, or oxygen 
requirements related to altitude.  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
93 
 APPENDIX G  NATIONAL EARLY WARNI NG SCORE  (NEW S)  
Criteria  Point Value  
Respiratory Rate (breaths per minute)  
≤8 +3 
9-11 +1 
12-20 0 
21-24 +2 
≥25 +3 
Oxygen Saturation (%)  
≤91 +3 
92-93 +2 
94-95 +1 
≥96 0 
Any Supplemental Oxygen  
Yes +2 
No 0 
Temperature in °C (°F)  
≤35.0 (95)  +3 
35.1-36.0 (95.1 -96.8)  +1 
36.1-38.0 (96.9 -100.4)  0 
38.1-39.0 (100.5 -102.2)  +1 
≥39.1 (≥102.3)  +2 
Systolic BP  
≤90 +3 
91-100 +2 
101-110 +1 
111-219 0 
≥220  +3 
Heart Rate (beats per minute)  
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
94 
 ≤40 +3 
41-50 +1 
51-90 0 
91-110 +1 
111-130 +2 
≥131  +3 
AVPU  
A 0 
V, P, or U  +3 
AVPU  - Alert, Voice, Pain, Unresponsive.  
 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
95 
  REFERENCES  13
                                            
1 Johns Hopkins University and Medicine - Coronavirus Resource Center. https://coronavirus.jhu.edu  
 
2 Guo T, Fan Y, Chen M, et al.  Cardiovascular implications of fatal outcomes of patients with coronavirus disease 
2019 (COVID -19).  JAMA Cardiol 2020, doi:10.1001/jamacardio.2020.1017.  
 
3 Klok FA, Kruip MJHA, van der Meer NJM, et al.  Incidence of thrombotic complications in critically ill ICU patients 
with COVID -19. Thrombosis Research 2020. Doi.org/10.1016/j.thromres.2020.04.013.  
 
4 WHO Timeline - COVI D-19. In: World Health Organization; 2020.  
 
5 Zhou F, Yu T, Dur R, et al.  Clinical course and risk factors for mortality of adult inpatients with COVID -19 in 
Wuhan, China: a retrospective cohort study.  Lancet 2020; 395:1054 -1062.  
 
6 Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for Progression Risk in Patients with COVID -19 
Pneumonia: the CALL Score. Clin Infect Dis  2020.  
 
7 Team CC -R. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Am ong Patients 
with Coronavirus Disease 2019 - United States, February 12 -March 28, 2020. MMWR Morb Mortal Wkly Rep 2020; 
69(13):382 -386. 
 
8 Guan WJ, Zhong NS. Clinical Characteristics of Covid -19 in China. Reply. N Engl J Med  2020; 382.  
 
9 Du Z, Xu X, Wu Y, Wang L, Cowling BJ, Meyers LA. Serial Interval of COVID -19 among Publicly Reported 
Confirmed Cases. Emerg Infect Dis  2020; 26(6).  
 
10 Kwong JC, Schwartz KL, Campitelli MA, et al.  Acute myocardial infarction after laboratory -confirmed infl uenza 
infection.  N Engl J Med 2018; 378: 345 -353. 
 
11 Yang X, Yu Y, Xu J, et al.  Clinical course and outcomes of critically ill patients with SARS -CoV-2 pneumonia in 
Wuhan, China: a single -centered, retrospective, observational study.   Lancet Respir Med 2020; doi: 
10.10.1016/S2213 -2600(20)30079 -5. 
  
12 Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 hospitalized patients with 2019 
novel coronavirus -infected pneumonia in Wuhan, China. JAMA  2020.  
 
13 Grasselli G, Zangrillo A,  Zanella A, et al.  Baseline characteristics and outcomes of 1591 patients infected with 
SARS -CoV-2 admitted to ICUs of the Lombardy Region, Italy.  JAMA 2020 doi: 10.1001/jama.2020.5394.  
 
14 Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical cha racteristics of coronavirus disease 2019 in 
China. N Engl J Med  2020.  
 
15 Liu W, Tao ZW, Lei W, Ming -Li Y, Kui L, Ling Z, et al. Analysis of factors associated with disease outcomes in 
hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl)  2020.  
 
16 Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID -19 and establishment of a 
host risk score: findings of 487 cases outside Wuhan. Crit Care 2020; 24(1):108.  
 
17 Vardavas CI, Nikitara K. COVID -19 and smoking: A  systematic review of the evidence. Tob Induc Dis  2020; 
18:20.  
 
 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
96 
                                                                                                                                                           
18 Liu M, He P, Liu HG, Wang XJ, Li FJ, Chen S, et al. [Clinical characteristics of 30 medical workers infected with 
new coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi  2020; 43(3):209 -214. 
 
19 Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, et al. [Clinical characteristics and outcomes of 112 
cardiovascular disease patients infected by 2019 -nCoV]. Zhonghua Xin Xue Guan Bing Za Zhi  2020; 48(0):E004.  
 
20 Goyal P, Choi JJ, Pinhe iro L, et al.  Clinical characteristics of COVID -19 in New York City.  N Engl J Med 2020, 
doi: 10.1056/NEJM12010419.  
 
21 Sattar N, McInnes IB, McMurray JJV.  Circulation 2020, doi: 10.1161/CIRCULATIONAHA.120.047659.  
 
22 Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 
2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223):507 -513. 
 
23 Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated Wi th Acute Respiratory Distress 
Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 
2020.  
 
24 Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, et al. Hospitalization Rates and 
Characteristics  of Patients Hospitalized with Laboratory -Confirmed Coronavirus Disease 2019 - COVID -NET, 14 
States, March 1 -30, 2020. MMWR Morb Mortal Wkly Rep  2020; 69(15):458 -464. 
 
25 Ni Lochlainn M, Lee KA, Sudre CH, Varsavsky T, Cardoso MJ, Menni C, et al. Key predict ors of attending 
hospital with COVID19: An association study from the COVID Symptom Tracker App in 2,618,948 individuals. 
medRxiv  2020:2020.2004.2025.20079251.  
 
26 Santoso A, Pranata R, Wibowo A, Al -Farabi MJ, Huang I, Antariksa B. Cardiac injury is associated with mortality 
and critically ill pneumonia in COVID -19: A meta -analysis. Am J Emerg Med  2020.  
 
27 Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and 
Outcomes of 1591 Patients Infected Wit h SARS -CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 
2020.  
 
28 ICNARC report on COVID -19 in critical care In: Intensive care national audit and research centre.  
 
29 He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of 
COVID -19. Nat Med  2020.  
 
30 To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior 
oropharyngeal saliva samples and serum antibody responses during infection by SARS -CoV-2: an observational 
cohort study. Lancet Infect Dis  2020.  
 
31 Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y, et al. Quantitative Detection and Viral Load Analysis of SARS -
CoV-2 in Infect ed Patients. Clin Infect Dis  2020.  
 
32 Chen W, Lan Y, Yuan X, Deng X, Li Y, Cai X, et al. Detectable 2019 -nCoV viral RNA in blood is a strong indicator 
for the further clinical severity. Emerg Microbes Infect  2020; 9(1):469 -473. 
 
33 Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al. Virological assessment of 
hospitalized patients with COVID -2019. Nature 2020.  
 
34 Chau NVV, Lam VT, Dung NT, Yen LM, Minh NNQ, Hung LM, et al. The natural history and transmission 
potential of asymptomatic SARS -CoV-2 infection . medRxiv  2020:2020.2004.2027.20082347.  
 
 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
97 
                                                                                                                                                           
35 Guo L, Ren L, Yang S, et al.  Profiling early humoral response to diagnose novel coronavirus disease (COVID -
19).  CID 2020  
  
36 Long Q, Liu N, Deng H, et al.  Antibody responses to SARS -CoV-2 in the patients with COVID -19.  Nature Med 
2020, doi.org/10.1038/s41591 -020-0897 -1. 
 
37 Qin C, Zhou L, Hu Z, et al.  Dysregulation of immune response in patients with COVID -19 in Wuhan China.  Clin 
Inf Dis 2020, doi: 10.1093 /cid/ciaa248.  
 
38 Wang F, Hou H, Luo Y, et al.  The laboratory tests and host immunity of COVID -19 patients with different severity 
of illness.  JCI Insight 2020, doi.org/10.1172/jci.insight.137799.  
 
39 Mulangu S, Dodd LE, Davey RT, Jr., Tshiani Mbaya O, Pro schan M, Mukadi D, et al. A Randomized, Controlled 
Trial of Ebola Virus Disease Therapeutics . N Engl J Med  2019; 381(24):2293 -2303.  
 
40 Beigel JH, Tomashek KM, Dodd, LE, et al.  Remdesivir for the treatment of Covid -19 – preliminary report.  N Engl 
J Med 2020, doi: 10.1056/NEJMoa2007764.  
 
41 Wang Y, Zhang D, Du G, et al.  Remdesivir in adults with severe COVID -19: a randomized, double -blind, 
placebo -controlled, multicenter trial.  Lancet 2020 doi.org/10.1016/S0140 -6736(20)31022 -9. 
 
42 Borba MGS, Val FFA, Sam paio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of High vs Low Doses of 
Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS -CoV-2) Infection: A Randomized Clinical Trial . JAMA Netw Open  2020; 
3(4):e208857.  
 
43 Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir -Ritonavir in Adults Hospitalized with 
Severe Covid -19. N Engl J Med  2020.  
 
44 Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a 
treatment of COVID -19: results of an open -label non -randomized clinical trial . Int J Antimicrob Agents  2020:105949.  
 
45 Joao C, Negi VS, Kazatchkin e MD, Bayry J, Kaveri SV. Passive Serum Therapy to Immunomodulation by IVIG: 
A Fascinating Journey of Antibodies. J Immunol  2018; 200(6):1957 -1963.  
 
46 Casadevall A, Pirofski LA. The convalescent sera option for containing COVID -19. J Clin Invest 2020; 
130(4):1545 -1548.  
 
47 Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS 
patients in Hong Kong. Eur J Clin Microbiol Infect Dis  2005; 24(1):44 -46. 
 
48 Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in 
severe COVID -19 patients. Proc Natl Acad Sci U S A 2020; 117(17):9490 -9496.  
49 Liu STH, Lin H, Baine M, et al.  Convalescent plasma treatment of severe COVID -19: A matched control study.  
medRxiv preprint. 2020 doi:https://doi.org/10.1101/2020.05.20.20102236.  
 
50 Joyner MJ, Wright RS, Fairweather D, et al.  Early safety indicators of COVID -19 convalescent plasma in 5,000 
patients.  medRxiv 2020. Doi: https://doi.org/10.1101/2020.05.20099879 . 
 
51 Work Group Report of the American Academy of Allergy, Asthma & Immunology. Update on the use of 
immunoglobulin in human disease: A review of evidence.  Perez EE et al.  J Allergy Clin Immunol. (2017). 
https://doi.org/10.1016/j.jaci.2016.09.023.  
 
 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
98 
                                                                                                                                                           
52 Shao Z, Feng Y, Zhong L, et al.  Clinical efficacy of intravenous immunoglobulin therapy in critical patients with 
COVID -19: A multicenter retrospective cohort study.  medRxIV doi.org/10.1101/2020.04.1  
 
53 Cao W, Liu X, Bai T, et al.  High-dose intravenous immunoglobulin as a therapeutic option for deteriorating 
patients with coronavirus disease 2019.  Open Forum Infectious Diseases 2020, doi: 10.1093/ofid/ofaa102.  
 
54 Reed EC et al.  Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus 
immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988; 109:783.  
  
55 Koduri PR et al. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous 
immunoglobulin --a report of eight patients. Am J Hematol 1999; 61:16.  
 
56 Whimbley E et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory 
syncytial virus disease in bone transplant recipients. Bone Marrow Transplant 1995; 16: 393.  
 
57 Kluge T et al, Rev Int Serv Sante Amees 1963; 36 Suppl: 59.  
 
58 Samuel D et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 
1993; 329:1842.  
 
59 MMWR  Recom m Rep. Human Rabies Prevention - United States, 1999 Recommendations of the Advisory 
Committee on Immunization Practices (ACIP); 1990; 48(RR -1):1. 
 
60 Davey  RT Jr. et al. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B 
infection (FLU -IVIG): a double -blind, randomised, placebo -controlled trial. Lancet Respir Med 2019; 7:951.  
 
61 Cheng Y, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong Eur J Clin Microbiol Infect 
Dis 2005; 24:44.  
  
62 Soo et al. Ret rospective comparison of convalescent plasma with continuing high dose methyl prednisolone 
treatment in SARS patients.  Clin Microbiol Infect 2004; 10:657 -658. 
 
63 Ho et al. Pentaglobin in steroid -resistant severe acute respiratory syndrome.  Int J Tuberc Lung Dis. 2004; 
8:1173.  
 
64 Stockman LJ et al. SARS: systematic review of treatment effects. PLoS Med 2005; 3:e343.  
 
65 Shen C, Wang Z, Zhao F, et al.  Treatment of 5 critically ill patients with COVID -19 with convalescent plasma.  
JAMA 2020; doi:10.1001/jama.2020.4783.  
 
66 Horowitz B, Price AM, Hamman J, Watklevicz.  Viral safety of solvent/detergent -treated blood products.  Blood 
Coagulation and Fibrinolysis (suppl) 1994; 5:S21 -S30. 
 
67 Kreil TR, Berting A, Kistner O, Kindermann J.  West Nile virus and the safety of plasma derivatives: verification of 
high safety margins, and the validity of predictions based on model virus data.  Transfusion 2003; 43:1023 -1028.  
 
68 Ham amoto Y, Harada S, Kobayashi S, et al.  A novel method for removal human immunodeficiency virus: 
filtration with previous porous polymeric membra nes.  Vox Sang 1989; 56:230 -236. 
 
69 Yuasu T, Ishikawa G, Manabe S, et al.  The particle size of hepatitis C vir us estimated by filtration through 
microporous regenerated cellulose fibre.  J General Virology 1991; 72:2021 -2024.  
 
70 Hämäläinen E, Suomela H, Ukkonen P.  Virus inactivation during intravenous immunoglobulin production.  Vox 
Sang 1992; 63: 6 -11. 
 
 
Protocol INSIGHT 013   Version 1.0, 20 Aug 2020  
Inpatient Treatment with  Anti-Coronavirus Immunoglobulin  IND # 23869  
99 
                                                                                                                                                           
71 Kempf C, Jentsch P, Poirier B, et al.  Virus inactivation during production of intravenous immunoglobulin.  
Transfusion 1991; 31:423 -427. 
 
72 Alliot C, Rapin JP, Besson M, Bedjaoui F, Messouak D. Pulmonary embolism after intravenous immunoglobulin. 
J R Soc Med  2001, 94(4):187 -188. 
73 Moser KM, LeMoine JR, Nachtwey FJ, Spragg RG. Deep venous thrombosis and pulmonary embolism. 
Frequency in a respiratory intensive care unit. JAMA  1981, 246(13):1422 -1424.  
74 Whitehead J.  Sample size calculations for ordered categoric al data.  Stat Med 1993; 12: 2257 -2271.  
 
75 U.S Food and Drug Administration. Emergency Use Authorization, Remdesivir. 
https://www.fda.gov/media/137566/download . Accessed May 17, 2020 . 
 
76 https://www.hematology.org/education/clinicians/guidelines -and-quality -care/clinical -practice -guideline s/venous -
thromboembolism -guidelines  
77 Schünemann HJ, Cushman M, Burnett AE, et al.  American Society of Hematology 2018 guidelines for 
management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.  
Blood Advances 2018; 2: 3198 -3225.  
 
78 Spyropoulos AC, Ageno W, Barnathan ES.  Hospital -based use of thromboprophylaxis in patients with COVID -
19.  Lancet 2020; 395: e75.  
  
79 The Acute Respiratory Distress Syndrome Network.  Ventilation with lower tidal volumes as compared with 
traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.  N Engl J Med 2000; 342: 
1301 -1308.  
 
80 https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/Adult -Patients  
81 https://www.fda.gov/safety/medical -product -safety -information/remdesivir -gilead -sciences -fda-warns -newly -
discovered -potential -drug-interaction -may-reduce  
82 Agresti A, Kateri M.  Categorical data analys is.  In: Lovric M, ed. International encyclopedia of statistical science.  
Berlin, Heidelberg: Springer, 2011.  
 
83 Gray RJ. A Class of K -Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. Annals of 
Statistics . 1988;16:1141 -1154.  
 
84 Fine JP and Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat 
Assoc . 1999;94:496 -509. 
 
85 Aalen OO and Johansen S. An Empirical Transition Matrix for Non -Homogeneous Markov Chains Based on 
Censored Observations. Scandinavian Journal of Statistics . 1978;5:141 -150. 
 
86 Lan KG, DeMets DL.  Discrete sequential boundaries for clinical trials.  Biometrika 1983; 70: 659 -663. 
 
87 O’Brien PC, Fleming TR.  A multiple testing procedure for clinical trials.  Biometrics 1979; 35: 549-556. 
 
88 Jennison C, Turnbull BW.  Group sequential methods with applications to clinical trials.  Ed.  Chapman & 
Hall/CRC, 2000.  